{
  "symbol": "CTSO",
  "company_name": "Cytosorbents Cor",
  "ir_website": "https://ir.cytosorbents.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference",
          "url": "https://ir.cytosorbents.com/news-releases/news-release-details/cytosorbents-participate-piper-sandler-36th-annual-healthcare",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![CytoSorbents Home Icon](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/logos/Home_Icon.svg) ![CytoSorbents logo](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/logos/CytoSorbents_Logo.svg) ](https://cytosorbents.com/)\n\n  * [Overview](/investor-relations)\n  * [Press Releases](/press-release)\n  * [Financial Results](/financial-results)\n  * [Events & Presentations](/events-presentations)\n  * [Stock Quote](/stock-quote)\n  * [Analyst Coverage](/analyst-coverage)\n  * [SEC Filings](/sec-filings)\n  * [Investor FAQ](/investor-faq)\n  * [Corporate Governance](/corporate-governance)\n\n\n\n# Press Release Details\n\n« [Back](#)\n\n## \n\nCytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference\n\nNov 26, 2024 \n\n| \n\n[PDF Version](/node/12021/pdf)\n\nPRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- [CytoSorbents Corporation](https://www.globenewswire.com/Tracker?data=jM7-HWTyDx0HEU4PdPBJcJe3Spe9MKF1PXKNwezmDPePBT4wwljzJVgLHNNfaWKm_x7MSLhuY9vw6_mxeJxt0RkCyH7b1BcNL04E61jZMnM=) (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today that management will participate at the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024, in New York, NY.\n\nDr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer, will participate in one-on-one investor meetings on Wednesday, December 4, 2024.\n\nFor more information or to schedule a meeting with management, please contact your Piper Sandler representative or contact the Company’s investor relations team at [ir@cytosorbents.com](https://www.globenewswire.com/Tracker?data=oWZh60FmFJsSkhU4ombdONUWGlS7CHMXniD_V_aFbbL8z6opfDCRgjVU8pYFJTvcWBfBTluENlPlZafmJAj4JCkPM002E-eovNGytdmXctIHwxhntGFuF8YSuZsDoymVUBc_eS5NXXCeywt-tU1fI-IqMzasKjbFbrdciBXxB19gtz0zxE_uahGYVR2gBK3xgfzdfGMrTJ0Boj0fEJjkOXeRHJIzGj5Q1cql_zJyOpRHODTyyoyO4pleeICoVeZ1Uaom6UVLTNDThq1NYAic5B7RJG2-M_tcQCf6Erm3ilrOixn9C0tgqyvse8SDAuWGQmxlnZHJ-UgYERG2wlmzhRIHW1OaHNOD9dlPUtM9AA19rdiEY19X0Dk_8mZw3mecyqmp4c2Hqtr5MluysmIkqc4ppdy5a7jTKREPrDIGGbo1lRJrlHRh0xOp_WdVztqZlmJO2Fm_6AEn6I3Nm-x1bMWC4L2kKLVCa3bLmW5aJZUe8w3ORN_L8FSto32ZK92YSW4qr0MJOLic1CVxR1bJqugOqFaU_mmD_wUbm7Bloc4MPeAQ7irkGPx_TZee3B5R6vM0YmP3hudNmGxVYKcZhaYx4-P6SWVT8JXsdkMztb1B9wEUXSTicAfRJ5e46gAnGfyT5dsXZU7I62kxd1EY5aVi8iWdvu2rxPFvG8dCbdIoeweuPBDmccJ3-0Ry3lieik6K9xk5CFA6vSjjoSDAhsP7-pPHuQVm9Ad9CEvrrUTh-_7l99-KQZIL3RfCYle_9TD4X6PrscjcSfvbX4QKUw==).\n\n**About CytoSorbents Corporation (NASDAQ: CTSO)**\n\n[CytoSorbents Corporation](https://www.globenewswire.com/Tracker?data=jM7-HWTyDx0HEU4PdPBJcJe3Spe9MKF1PXKNwezmDPefk4M6CFN4z-mEe2lQwbCyXE4tonv4_pJf4Br93A83Aw21DzkREg4mij6WugresKw=) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, ECMO, heart-lung machines). CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.\n\nCytoSorbents’ lead product, [CytoSorb®](https://www.globenewswire.com/Tracker?data=jM7-HWTyDx0HEU4PdPBJcOV-PSexug9l1UlyHyc2kSTiQyVfQ3FtgqpNz1L3qxarNbYsIHgOE96OQKWUK8dHxg==), is approved in the European Union and distributed in 76 countries worldwide, with more than 250,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for [ticagrelor](https://www.globenewswire.com/Tracker?data=zE8bQqX_PVLb4GtRBKWiyv9ZnUIbDnp1z2yMo9Ihm8YUQgyFrez2f1GBOmujW-UfJ96F7FFVHrdUXBfdcaEMZjbxNLMhBS-QESJaXeRTpMD70IzLnpkJ9_fLrcMlkufy24RL4-CUtADjN-KMbbE36v4P867-EyWDj8zZQZotjbPLkdfHXKW9D9M8QPnO-H4M2BMzAX0Q5VLtFH90gAV62LOyo5uxMtWv0m7Wmvwz6iavnnisd3T1oIHabBLnMtQAY-fW84JCO9O2RKQlYMYC0ODSpzlpOUtkCkQzTqD6FPY=) and [rivaroxaban](https://www.globenewswire.com/Tracker?data=YhxxFwZ5j5xMbDiKjXBvArImWxkaNnG3OP2A2rplKpIix6K_aeXq-YquajGoMSEA2SYyvn2T0UGdpiTUjgWva0wdQkhaZat4dn37TaDipCqWtrdzb8WISX-nJ_YdiAzxY-5X54A71R14E-zSf1Tj2-T1zQMjGioDYaBzh-zViasgQ9hNgnO5NLAaNniqU85qfjGiE6AZ1wqcWMdgrQH0KTqYZ7StL2ew5a8cEBvzKNK4E4wgNZhXDyzubPCNvvyUgoJGf39RLIvHO051asB4bj9lXBdL0vTO58H_8rcRZ8esv5-utDXk_DwUxGneyCZa) removal in cardiothoracic surgery procedures. CytoSorb has also received [FDA Emergency Use Authorization](https://www.globenewswire.com/Tracker?data=TMCZs60O-eIM58K_nIWXgm4FA1YaimJUEedxdeyAouU6vvx6JH90mGvNMaBFCVUngSntYAMHaX79Az2dMPDYzzwCHyOyTSvQiWjdr9Qnxk9rWNxSpoGxl6YK1eYvcrdurk_KXwV0vxITcd4io4qzGf1mpGJbaYQJel4KezrFiFiPO7aZoGrK1aN27FXGUPyKHGd_oP1D711APmo5ki5AXaRIxvyoTkaaw9pxKvrhs9zhR9nP264IeIYFf2nrGGtwleiCCAme5D7y91IRBpOfEQ==) in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure, to reduce pro-inflammatory cytokine levels. CytoSorb is not yet approved in the United States.\n\nIn the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two [FDA Breakthrough Device Designations](https://www.globenewswire.com/Tracker?data=kO0EhmfEAZTLynlrqG3tvtqbMLZuG24zLIWzmwxwuwcXulfR-AMBbFSiXIFH669XYRFhiqoAckFLeNFMVDo3_Il17ObdvYjSmkB34-lOmz_2AD-qcstglzspaChxOp5v4qbY8XtJNmgUvhb6O1WxWmc9qgyVexRfneKBwKyr4BfOSOajTIGhiBCFcrMb4OFziq2l9FEeYo9dxIfKfhX1Vl7B_VjFwMXus7jQXA8bBxDlK3OAfcYCKgU3h1hHxT3SrCT2Ra-FqC-IHti1Xn8bSVjhaiAhdvCAEi7J9o3lL_bHvfEcO6C3fLIUJB4zBbIkz_o2_PVeuT2V6Wex41NUBEU2G0I0dfkb-Y_KZtHckSFyVKB6YBXimpalEV4dXZQU): one for the removal of [ticagrelor](https://www.globenewswire.com/Tracker?data=zE8bQqX_PVLb4GtRBKWiypIfIoWCcvzbgNRW3hKkm-DHHfrVxdjI1sfgmxX1uK0TfBa3I_w8hOTZ_VCRjtHFpsza2sH94DhvKPUU-AKZ7pfDOLGAeOMn_wAKAYSwn_XzHn56XHuKR-H3HwBlGZQOvTlyagsnaTlORcJ6lSDsRVJch42Uf_Ir-Anw7CSDCQJ10N6dUZPmFfRZERrdXKS_9YyuVOujUX0ewU3BlLp2uyTY0UWLT5ucNYITB92hjjc3htJbeWUWI5xJz8w1gcztMarhgxBEQ-HhA7u-oOEdQghBpc5gsvbzvslpqnigybERZIH7ySqceOSb3sprrLNmPCUFZKpurHI85bttz3PpDts=) and another for the removal of the [direct oral anticoagulants (DOAC) apixaban and rivaroxaban](https://www.globenewswire.com/Tracker?data=MH52ouWRvjujxCQXGX0aJGdv6mKFdNrzhEw9jTQ_J2u6exX-gK31hZRVl-jFlrhyYKD4qMANuXlPZ6s7MEH3S3KlPopsfiNN7eZHPAWt-IKcLP1hip2N5cQcmmnrdHPttDfjpME6VT087neIJxXJhJDz372sx1iy_1ClU5RO3Wuy3Y4OQfnSwbK9xPS3yfJeIHM11bBoCnkD0wNcaXLV7cKBvnFBoX1pWaw7KKjISiBFmi7kp6fUVuFp49g9itZyuDjqImz-oL07lH6ASlJDUHPRquu5L1UbMJ-CGsbLqTcjCaf9BrJyhbWe6W1LDK4D0DDITBZoFXE_IRmAd5qDiejKdgYgA7CGTd-bgmKbKaR7jPTwXL_UMKb99944eXWyWa8WYyB7v2J_CW8wIrjZwPLFYvnJpKtKgRL7Nzk7sywMWf2jcRFF8uL-6sKJMis8JEYiRzPq20--JXIIrnAQSA==) in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. In September 2024, the Company submitted a De Novo medical device application to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024. In November 2024, the Company received its Medical Device Single Audit Program (MDSAP) certification and submitted its Medical Device License (MDL) application to Health Canada. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively.\n\nThe Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company’s website at [www.cytosorbents.com](https://www.globenewswire.com/Tracker?data=bpLn7NVCFe-bPZFXAKBGtV5WvqdiQiIJOvl66Dl9gZxoJd4OvYnaUWkkPEVtScIGmTIWIf0uDGlKHjhWaJ_PwlyTyz3CCBjn7VICTl33GIU=) or follow us on [Facebook](https://www.globenewswire.com/Tracker?data=9qx_k-35KUJE_tOsmKlv2F3hUUpO9zsOuk47r14sjtzK4fsB6_TuEoE7vRN8jmkxThGrGMDTWlaQkP7-kS1cYS-lp-ROTcs8cImeoS4l7KM=) and [X](https://www.globenewswire.com/Tracker?data=c3xQoUUxw6rh2N77omwvTRXJ5H8Bd4_HqCd_8PP1W48iAV7DFvGd4ly-U8qxR_gLW8FLnlxhv-Sldr4Kk0RHgA==). \n\n**Forward-Looking Statements**\n\nThis press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.\n\n**U.S. Company Contact:**Peter J. Mariani, Chief Financial Officer305 College Road EastPrinceton, NJ 08540[pmariani@cytosorbents.com](https://www.globenewswire.com/Tracker?data=KjiwyhccEkxlIlS7lhlY3Aoim0NZ0EOLVfOX8eaQlVQkdb8XdGIWQi_okaiF-oeVi-9myRZToDYtDM7W6UZS1GxoqP2MdInMxRL_E3GDAuD8xNf_lraDWN-gbIcZ1Srb)\n\n**Investor Relations Contact:** Aman Patel, CFA ICR-Westwicke [ir@cytosorbents.com](https://www.globenewswire.com/Tracker?data=oWZh60FmFJsSkhU4ombdOGLQp01L4TNbvDky2n55GNGyV4wFUHV6YQSFSA4FdvAEU9QySWSL1XX3BKtRZ3q_wkePoCbLczBDzeahB3qplKirGsLScYJCoC7ff42TlzWxxHUFDTOztQyQeaNvRxTklLswLeH0KN8ILGDUxPoCveHseO6CeGVt41UB456F_I1CV31zHi-J9inj6_gSzQc_Y9nRKYLgWtDO-s_BqgB662yFvI4Ns0tZwWtb-v2l65YS3CUq-s3xUCeWtUPyzMExlW4E9PS3__c2IoIS3rEzgboBePMiPczoAyBp1Qb7Eq29folFREODcUMmPc-ckw2GC9GDMsDsQCuH2HZbP6McfWTGdG65OC6h56nHR2StP0Uyv68QDAjhFplQNnQO9VVD53e6FYKCAAZOQiJtdZMZse6kYh8HmIjhoeWdYH2ju293cExr3FkJXwkoUg2fPvhMcZnM5DKOONQiru_2-b6JhTeLHI70XIGYTA5jYaq2P9Ys8dHPE3YxEauRVkCOFCr-XwacFPfEJcWHB8Uyd2_TMrZOJJUkh-lKIl38AmH-7HkwqbAp88Z7knhQsY9iPyx2GKdrHUsFTu5n_g9N6l4Pr4Be_NN4rhvi7mDWNUQMegQ8xjrUMpB9n45QS-giXQL7xWQlMqgth7ehASD32j3EgaFpUC5bD_4Z9-S_ZSkUdwQUC8yUipHM5aqnVwopCbXBgxx_t3SKzVcxEEa-r1uNUrWsAYdCm2jAtPkJ5hakxllNanK5FjsLUFkmQJht40w_Ww==)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI5MDA5NiM2NjExMjUxIzIwMjg2MTU=)![](https://ml.globenewswire.com/media/YmUxYWUzODktMjQzYi00NjJhLWFjYWEtZDFkOWYzODcxNDY1LTEwNDAwMTk=/tiny/CytoSorbents.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/7d55186f-ce46-45ab-b1c2-fd0c843890aa/small/logo-1200x628-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/7d55186f-ce46-45ab-b1c2-fd0c843890aa)\n\nSource: CytoSorbents\n\n  * [Print Page![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/print-regular.svg)]()\n  * [Email Alerts![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/envelope-regular.svg)](/email-alerts)\n  * [RSS Feeds![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/rss-solid.svg)](/rss-feeds)\n  * [Contact IR![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/users-medical-regular.svg)](/contact-ir)\n\n\n\nRequest Email Alerts\n\n[](#)\n"
        },
        {
          "title": "CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India",
          "url": "https://ir.cytosorbents.com/news-releases/news-release-details/cytosorbents-and-converge-biotech-announce-strategic-partnership",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![CytoSorbents Home Icon](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/logos/Home_Icon.svg) ![CytoSorbents logo](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/logos/CytoSorbents_Logo.svg) ](https://cytosorbents.com/)\n\n  * [Overview](/investor-relations)\n  * [Press Releases](/press-release)\n  * [Financial Results](/financial-results)\n  * [Events & Presentations](/events-presentations)\n  * [Stock Quote](/stock-quote)\n  * [Analyst Coverage](/analyst-coverage)\n  * [SEC Filings](/sec-filings)\n  * [Investor FAQ](/investor-faq)\n  * [Corporate Governance](/corporate-governance)\n\n\n\n# Press Release Details\n\n« [Back](#)\n\n## \n\nCytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India\n\nNov 11, 2024 \n\n| \n\n[PDF Version](/node/12011/pdf)\n\nPRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- [CytoSorbents Corporation](https://www.globenewswire.com/Tracker?data=T_jbjD-zNve8PjoMXwgBD_ZhV0pCZ0mboMj1OIUW9KtlnyIV8Qy7055B_F8QNuqThNwara_md2dWTeQO6HSgAnQlnkuQ2pYPzQ2pewq4bro=) (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and [Converge Biotech](https://www.globenewswire.com/Tracker?data=3esHMckuEZap9k7OhIRAGFpDMQOinaE8tut8Q0S7qjHabR_knY7KyCBixASGZfQ3iwHSrZ5vbnkC47PgwRhxSlFuihsqkQET6Jd7ljxMY1Q=), a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio.\n\nCytoSorbents is renowned for its flagship product, [CytoSorb®](https://www.globenewswire.com/Tracker?data=T_jbjD-zNve8PjoMXwgBD5nZP5FaZFRdFnvCHOhwuEntIvBCknzCcX7DxNYgSfTueL-5H9dCGgbwF6kJFi-qrggubDHbMpFRNXt4Ti6MYvM=), a blood purification technology that reduces “cytokine storm” and a broad range of inflammatory toxins that can otherwise lead to massive inflammation, organ failure and death in many critical illnesses that are very common in India such as sepsis and septic shock, lung failure, acute liver disease, trauma, burn injury, pancreatitis, and others. The therapy is also used to treat acute liver disease and trauma through the removal of harmful substances such as bilirubin and myoglobin, respectively. CytoSorb is used in 76 countries worldwide with more than a quarter million treatments administered to date.\n\nConverge Biotech will leverage its extensive critical care sales force and strong hospital network to accelerate CytoSorb's market penetration in India, ensuring more healthcare facilities have access to this critical therapy. In doing so, CytoSorb will help Converge Biotech strengthen its existing intensive care unit (ICU) portfolio to now include the treatment of sepsis and other life-threatening diseases. With CytoSorbents' innovative technology and Converge's established critical care presence, the two companies plan to expand the availability of life-saving blood purification products to healthcare professionals throughout India, with the goal of improved patient outcomes in hospitals and ICUs across the country.\n\n\"We look forward to a great collaboration with Converge Biotech to make CytoSorb more broadly available to physicians across India to treat complex diseases like septic shock, acute respiratory distress syndrome, liver failure and many others,\" said Dr. Phillip Chan, Chief Executive Officer at CytoSorbents. \"With our unique therapy and Converge Biotech’s local expertise, distribution capabilities, relationships within the Indian healthcare market, focused critical care sales team, complementary therapy portfolio, and market strength, we believe this partnership can help drive the growth of both companies for years to come in one of the fastest-growing critical care markets globally.”\n\n\"We are extremely excited to join forces with CytoSorbents and make CytoSorb therapy accessible to patients who urgently need it in India, helping to save more lives,\" said Arunkumar Bijjala, Managing Director of Converge Biotech. \"Our mission has always been to provide innovative and life-saving therapies in the critical care space, and CytoSorb represents a highly impactful solution for sepsis and other critical illnesses that are major challenges for physicians in the ICU. This partnership will allow us to significantly expand our offerings and reinforce our position as a leading player in the critical care segment.\"\n\nThe collaboration signifies a new chapter, empowering both organizations to drive the adoption of advanced therapies for critical illnesses in India.\n\n**About Converge Biotech**\n\nConverge Biotech is a fast-growing pharmaceutical company in India specializing in the critical care segment. With a strong presence in ICU settings, Converge is committed to bringing innovative, life-saving therapies to patients in India and improving patient care outcomes.For more information on Converge, please visit [www.convergebio.in](https://www.globenewswire.com/Tracker?data=dgm87mzc4jyBtOpAZVnnIHw762CGewbiogj_hyjxwo20gOKKfM0Lc0jxQv7wf_QG_vvHiUKdFUaiNh0VWBRBazBleHYlRVgYigVOpBuOwEw=)\n\n**About CytoSorbents Corporation (NASDAQ: CTSO)**\n\n[CytoSorbents Corporation](https://www.globenewswire.com/Tracker?data=T_jbjD-zNve8PjoMXwgBD_ZhV0pCZ0mboMj1OIUW9KsmHbWU6_R92nXbJNWvzC9s2q4bcv7x7zkmf_2doMRTum8jOk4KCcmA101iPL-hCBw=) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, ECMO, heart-lung machines). CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.\n\nCytoSorbents’ lead product, [CytoSorb](https://www.globenewswire.com/Tracker?data=T_jbjD-zNve8PjoMXwgBD_q2_gtOq6b56bEvDQ-qf4ljIcVBFJmyPMA9mhRG2uIeZbbCkw1JORhVUods41LhUKeko2bL3Ao5xGS9cKD61jpa6tlEGf80kp_p_pJjjyJQeRxExI0EsPolEmdte4b1Q3_2U0tP_VTiummM6tasckTHIq0ItS6bnZ2Dhh9aVJy1ujPJ3RqBSdGF6Cvz7hd9hY7DhAVC9X-mWH2WBwgopQoWRe66zyrRZI2jTxpIt6n397w1Yqof4OMmnaaq7VtPSB7TdK0dq_IP4lMBZjM2tJsLwdiwmVQV5C6CULFsgH-8E6vFDpQi62qer3aWd-4fnMiIjHv4MPpjF4RMUynMxJUjfTgP2qtnWt99Y9dxz8EOunZQG5XN0BGprYnoB1k4NNyBSKV8BkT3ERYLeN5FWagxWWC-_7YNVbgvJVjt5hBD1AA9UNEIG69M6vXh3VU8Z_C2buhvEdCwmMSTSJ31qhnO8bWRdf3zucKz0XQslTMYV7nS1wUog2lA0TqiCEhpOoBZtb0XwRQET_UZwB8V_iIvYPerz8LeycnVVxeZRc5WqVBGZJ5kwI3q6rzVB2fVaBAFir1HgbytNk35Q2vMEtn3Ne3VLw0eqeYHPpFf2UvwMB0okiTEUJkp4z43rOe5HDedsb_pQrVHPoA8-tpjB6o=)®, is approved in the European Union and distributed in 76 countries worldwide, with more than 250,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for [ticagrelor](https://www.globenewswire.com/Tracker?data=DduLHxf0NoVOk9-2YVQIP7_d0H3cmUpac2KNsiw8hz0pnZoT8tILFUFfdtBFH5XryaNADLRqKkW3IgWs1WWw-c6lBmr3JTj3Jc8ZxQ6H2zIKzVl4tJEx0wiaaz2Jwgag92-Yf54auAWG_dxCDzty8fZWOhk2IT2HMJ83NIdUXArtKoDxeVLcpdnAJMqBMkLzjhsg9LQCbW2smL9iq8YeS5Q0ViuGyB87xpohADrh4_t0yMlpGanJqJ4qDqEETnsKtzWPnasII6cROLHXlKvGiMVmskPHUu-qJyPql37minMxCXL7AQsNL0PpIrXSBK1mCdunjBEiYxgEkaDJ5TOOiNuj4Sk0K88NaLZ5RbFRVf7l1-fG_5cAT8LjLSpdvkzgTYmbH6U3CEF37enCSMra4UhJOqm5Wj_RmwZuABvW5FFO8P40GRR2oetHtWldTgoYTVGKa2e8_2Niy8mV5c8R-7BILDoRCwEAf06cvq4tDVPIcW_J7F7u2k4FzAfnreMoFNRladgZEzN2_uL3vJs_1M9VgDudxqx7co9YP3ivCmRNLLd32DJMhO1tPmBglVUw-A_3oS9Mmd3LQU034yg02QM94vdGkXVyUn5ZtkfgMbtzt-dvH1dHgId6ZALnacipxJE9na6sVGd_Acjl0C5ePrq-x1vtTNE3a0wpWzLibR2CKGMCDuS_19iZGdT-jds6tAHZ1AM2qybb2zCFd7GFasX-hdyF174FOlYZtpyvfshqKb84MHguhiM5MOGwpdSN0SsJqVpYPYaINvTwm-xIY42Vdbcbaw6s8KcLHg7hmmdkuzsdYY_A0e_Vi1U_c8rw0ruzfhfglAIXSiYuRbY4VlXScilMfm_UU9OrZOWwQFFPaOlP6_zoGMPD4OesZFc6qcQMjtV1PTeRXClXsKqKPLjqEe7rlLxGr1sUQv2QnseFqnajAyv-EULNrCAX5nWQoWPakObJKbkXNQ555v8dvE_-cSLDpuCbomygEqYfw7iY8eTUZ1C_NpxWjgV5mkYmOrkc_lcdcpn0fM9-ojekcTZF3nvoTjJ4iGHkanVEDmfOsskzfoZd71OD3b6jK_fYgc_IeVEqHMLLP4z5r9EhL7rUC3YbYcYf7QJzdOH-N2gMqamkHRkrWPCxn3tViIzbsPWQhgHB5KMMMdg3CPEs0g==) and [rivaroxaban](https://www.globenewswire.com/Tracker?data=TklH3bTE5cDl2FskOmcvK3rwZUOGo2VMwq17oyQ0YUMIMLCn9MCHZ17hbY7I9N6mRs-mrgxO7TZvz1Ap7isjWFxtxD49EAaw3Od52xEFqB53VSwq0aMT0CjpY-WK8nlyNpPAu_YxzXDYp7yBaIh2pnFQBrqnlHqxwDVSQeYPKW-bKrjO3yEq_SY1gJ5_GruaJBHAimozriQG3Xurc96q-9MB5aREY9HsW2v0ypk2J4K1XOcdrYQ1To6TJLG71o0f1rpMD6jIfZLwaBBz-c2YVXsaJSU8tsP5gu7i7Qs7Sd-pxM6iazy0Tjb5DKD0JQRbPR7VefszTBO1pAoQAPBO0tpM6mUeztNgIEfq0CW8JsuCs-oiBA0Gr2KXRqclCAOtgrLyKsSYxmRDae42TkEH-qVi8gcHlOMaLNRaSe6V6Phsh88GBdtb7yGA_bb0Nw7aW1E5DyZ7s3CQPTqYeZB3O5NO1bhuNR3Dk3nObRwpQAj3uEFfY7Pl2MrOBd9LBwhHxDy2ovLQV70KrtOlJnzoi47Y7OB7_1SdkYRL6mt9z_Pzh3aS_-FLT-YONKfs15Egw_LUOnRqvD02rvW_xQGElj8lhQUZjFzjhg9W3PYtauTWwBIezk7iMkbLKFGD0nH3n0OcLpTHmq7hYeZC24ue1PVp52OrD2aUAGvJSw826SeZQFLMevhJNU5frHj9V2KmdUI-15-3xiMGmbaKk7YmdBkMeSQAsl5cB-qqbWZV6NgiguE9Qeke_YNwoXMyuly8knj2OaeJRCxhCfLBP2aJDjqK-fczM1UBag63AKqZ7p0jE5Waqah2pP6HuuzFb3QkGRLorkjs9bkGmvJtICiIDSt4sQtkhrbEqrmCWqe_ie9wJxMJmnHALghwl_ZV0zqBCKhXJZ27_YnysqYAlqHSZJDS3FJhA5LNHUdYbAYBVOuKMymOo8khhO_JL_N8T9hWxCPg92ypCbMdWlylaNhwi6TPfuyslDATwqNawR-NYI_HgcfAaB-GJxCK7AQ_ZMa5a5AfzeljgOuo1qLCLgxWqCEPNQF-MwoK9g0dUCixq3rV9bTVaQyPTjfCKQoiKfLZTkQatvvPlvndkZBnuJUVuvkhwKU-xnpuwtuTFtLqE3MuCq-cG6_eMW-j5PBBjCbh8iZotA9Bks3EEiij5a-zSoSuyqjbie4qbYESIBXlE-j3l6dEoOb4AsE-XogNG00h) removal in cardiothoracic surgery procedures. CytoSorb has also received [FDA Emergency Use Authorization](https://www.globenewswire.com/Tracker?data=n3V7_u1-Mj14XXPvtLk-2G94ZPLBD4CiNQirZ-FPouXW0jOYMyoW9wfExQYGzYWMAemqrNivU96yOqduDlbDx7bU5G1Z8MkUhHrEr0jzrSAvr9TgbPbmJLGH2do6NVMKaa2D6Ve0P_nlzFz_kpYwerkwF-3c5lKFyrJ2K0HvgDTfcjYv2eEBe1OMKsdPBcvYcjYz9r9GOQgoReDxD1T6icd3IYw12Ufch8ZFzjKeLfsZypqO3RS5vb7ONeKq8LaHZnktcpHTlNgDV15BkcJQ0qPp0NUinyAD-zdSvxNxePB09ZPcq2OGTOQ8w9fG2DK5vA1X0ozuVEZIAdzHscTkfFNTnigYAH5uGQcsBk4cOL7-feiBkzb_1zQuks7XAc6OKBOjXlNZSx35uBAI1Lsaj2r3dxWhLq7UuKbK8Q5EdDs-Y1iO3txVBxTp35_wGXY40jvAp-cniEIsNQFuIc--CxeE24F1IfWQiR-3Pd9NjN3f3xYPOBHvCzyYdyMngGdtEonppIDoaegNsBZQVJNmto1zMxmx80nM_9UAd1uMT9Ds39HlDI7zZUhIsmc780tHo2f3O63E7mcZLjdbvFr16Ycs8aPU9OgDLZ3IppmiC3-p-OtKIUQezqWWUW3uoaSJ9QGTkDbvMhqNspEF-wlgJ4hmXLCcDOqpRZf2OKKvLZKKaqcKkIoHtLlJvo6qZAw7D7H-X1XcVz1mpQnp2AW8aBnVVRQMO11uMbdPp4Xlz7NJeNQVFaceay0jHfW2vgUr3zz9fouO09fnjH-KJyxLQUv3Z2zBcNIw2rlnFGFmsm6IdZsoRe2rV-N3KZVKpqhMPsanjxD6LCIxbauosT03z48YdHgMyZ5HQ8QVe9UrUbTaUC4JrHws6dwYTVeixR4sTHxnMd1pMNfDybxx40PFBavgfq27GwPX_OcWO7xV_Inq0D6t6sR1wxJkfvX8jtRtw3UkxkHj1d6BPZLlerAJq0-aIPvV4rHpIgviw1H1b8xyhbpl6xtAu6evzK-p-KAR1hXYTROOQ8wv1b_EczKU0qMG9TFSd7_CcOCk5_Z7p3beovByB8CPYtVbyUVT7PUrtVYWKbGRsezusXRYaltz-dS0Ty9f1SerTLo3O67-7e_yai_s1dCnnEW1hbKAc6wA7rBNdPJ_r5yocHNO_BxgLSeA23Zrza_52eJ-SvAYYTZtlc4pn0OzxaZCKMhfGRymJFas98xuhBk-LZHjpOWlN6A2yiXgDRVc1NnQeZr3ZPQ=) in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure, to reduce pro-inflammatory cytokine levels. CytoSorb is not yet approved in the United States.\n\nIn the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two [FDA Breakthrough Device Designations](https://www.globenewswire.com/Tracker?data=r75nL7BaIIwfxqEEfz6-jX0rpn7iGvBFjV0zc8USZbTknpRFpOp3dalea9X2Fb6cQsvdlB28aIPCUetnbqiUhqxsgR0TNE9rHhtsItC4JFN2MSBcgfbx0IYDDolVPoalSvGHoGL00o-3ifqUtZB3GanQGOZuGlm5F6KGELOGfK8dmAjF3YY-kTj6B9VbxbsSfzsifMKcrr5xsljBb2HLMoF3ek5-aFwAWdwwZhVTS4P611nMrKx4TLGquU7aPVI7KKgfBg14bBP108MPSehmP2j7GUMaHHfqyMy-uGHmn-dhRlJx-G1e-CxQF2-nfLEb1bWK-VrwphqH-7dBAR9l2o4G_iPoAqHkDpBXSNrdQexK8ZOC-9IGmOGim76BO07h2-2-FWIKlkjPu_CTdI9K-vwKCZ9a12pBm1nyE3YC4iP9AK61L_o6PmJVYS-26qQMJPB9fEcMi7N6DkNqG7ahrNw9ue1hrYF756ggISQhfgtoz5nrdeeIMU5JawD5Pdh34VGbtpWpjglqT-jSv91oEVQgl6ihBhHJ0_C_wJxSwqO7d_41DIKVKEDwKnE8pYIzy6t87x156FexNZUKMFMDJ9TkyTVLCUBBISaBvR5h-oEzu2KEn4l_fXXkotcW0F4E4VdxqxiNmsdlfP-NXuAq05UHA68AsZFKO4PFTfqdq1fVZdPr5IPgTgrCEt1mrD6qiiuvUh1wxxguSO-QFRW7UgBtqWXLeATpYgHIdHPMnSrszqkIjUg1quMLyY8A00S8eZvD-p1qABpUwsknOHrQ9aVexQh0fQUfVVLfiBkC6C9D-Cf__EgUZokkJQbYfPJIERproHawnRV_mD33at_ek8Ky98RuRFXfru0AlSBOXng3WwZZt4DbovOvlCZPne1PDxCTOZ0jTk3UtsQVdnJs-DY0DzzAPmiV-5EAHXMUAgfyEH1WRFb-gO_eToITPQw0KLDBV2mZV9TloHbrtmVw2erTOMj6BJJ-0icxmUbm7NuSPko4ciy3Je7jms4cUA0f8e4NOEltu6zxw41hj8Qq5ddXY4QDZ6yK5lcgyzUvRq3GAwL-pJwDTDMLmSchmm6kVjTzVbIeWsriF3FXZSBnHDmyadPYnebVNQ6iLWwgD2SidLkbS5kq0_lhArHKLIEql-28PgfQg2yly3UEeJ77WwYVud3dNT2j07T-joEkLl_sHOsb6Panffgxl26_uuiN_YAAH5B1BogVuZBq_KVw3n7QAvcU3lVYUGexcH4IC837hjmPeaafghsB1nKrHJB091IFUq1CzNGVEnsk6i3c6XISxPRIkR44hiXWvTzN6II6HCrlPgrAPDOAqPxrQsqznZL24HR4nl_qsoo_3pT_xLEoZKJHGgxNMMoFhUykBgb7DtKUve64yyemtHGf8OD790Jo9Y0keD5MRfDqEA9yrSVNzlzqBC9sduxLuGqBU18ik5tgBdPi8q6fnRTFHafNOzfnOgY18FEmQCdCUyBH_bwOFynYVf5A3hlrTVkv0r4=): one for the removal of [ticagrelor](https://www.globenewswire.com/Tracker?data=DduLHxf0NoVOk9-2YVQIPyV4UkaLMaGhtNjIjUFRcZdPrAVxzS3y8OSTRQXfRBiyEVIiAh0scLdWh7zGAJw7hO-IEaZazutaZV2QZtrwWg5e682db713GlVEgMF5lzYGSagBtFIbwJEGwoKF1j_W8Zz4UypSbw8sbSkVIznRRi8iqjLN526eFBoqsBGsD8d6B7BSKrTlffTxTWd0Ky7IpeeUp3rcxTQAjYYfZpn3IXJqflqWZDgXO5mTHQECzA5Pon1hZGeC7c_2F60uAkpJ4vgDyqDTJaK-nRPDc97PIj_mi6d8lNJhZ40ad_IjLRDlGPxvEMYIhF2pL4H5e2a_n-y854WvttkdAYgufxF6xjPQ0tFyb7XJiPHb00RWTPPvusO9t8rop4AR7Y5ujrWW_PKjyT6Xf_vli51zvGSaW8swPp4rbs8d3qYnsh0fhDTWwTafO3tA4ukhM6hbJ9G4e3cneD_VNDk-H2jZEMuLoWMmSHBxBMgTQv5pEwDOBbpPr2EMSqJJpzoVoOMUUTTlRrZwjDRxU9TB-k4IZ5FawoKygleADjN5-Q4SLZxu8bpy_-Iva2GsKDvgigMIKC0SQHHcDV3MgQrMhURBT58QpbEGJm4HZFALG14SRX0PKHmSk-7tH0tfJFf2E7W7ZaWY0wncp2fs7RcDFetkyMyWaIFh40KG-c6R6Xup-yFN4z-W4WmwNDzpeD4OY80FF8RpVYnHwW6qoUAh88H7uL3WFJeS4tF8LlDM5f0XnNCV-DmlYKHJqJXVyksYpi5oyPUcwOZob2GI0NsN_PZLwhMKzLureyX2z-nIM9D41NUArhJ9DnjxLbDl-DHaMGlw11SNXneZiDfFxJEBNBlmb8crhnPbTGKTWIetL8HM0EACmbtWgYRFfbjYEjWiLCFVAGmuZnX5OMokyABiY1gF7xY1qebwTvltrEaPAOCKujJD9R1EKjUJvGIk5att3Tyy17Lcjmin2_4hsIi28G9Nacw0aq2rpPuivl56x4yZKUbL_0xuBg9eTlXVSzigx5tkyjkBjzQzuRjti5R8PcjK6xbE1LwwwaHd36gBIaPj_1bMC-S4cn2ZV8mapPn1zoU_fha3JepaSut9s_EZaAj-vJPePCGvFnREiI7HpkPla_fFn15iSPjLV2RAfyhmXDTLdWzqWlh5I_lfSB7lplZfqfaqNsQ-ZSVdj9YrIC7bJvgscrOPMtsj13kHdJB1lGZXziWLIWqAQJm2cQ3FCkmFeNl6LuIlkNUBMP-syhnlP8QhIFZ_AK9AUej337KhldS2mFFMEsOutOrszKGZ8hefL6jFgdX5i8VoDxT1oNhYBQgnbl-n) and another for the removal of the [direct oral anticoagulants (DOAC) apixaban and rivaroxaban](https://www.globenewswire.com/Tracker?data=57eK3C6P7DTd8F3mR8n6Ytc5YnhiVUNEEYvIFXbJP4KNQuGKAjRfM-gNjx17sCV4Ip9HA78de5bvibgAs3OFdg-LpuA4Et9RhFPyLIU6tOMCZ82s9YIe1K3YYDeeIIl-bDakhkGWQAkUy_0RsgVyW1o2TpgGt4iQ-kP6p2_u2GrQPYPNXleQBChn5ZsS-Jk4M_xQVn-wRxDgEU08hPea5C7TDnz3-aG7a2dR_yEc7w20xWKvMCCdz3nyq1L8ueiDhriUIZIeTNTdfdKGFzAfWAcvR1IJG4gOBrlhMaUT5vOtFGHN7cJmA9z-FP4fa7idTKtt3ouS23lB0BG1djwJXfDFtusgZ8ZkJL_JZsWLnoShjeE4jL3QaSIoC_N7SDs9wMy0E8egNAyBblT1HSb0Lmug3gigWrVbsAP_P5HbK7DTZbSO7ubwrSy11TBHb5Rz0ZFmp_UXiis0MMmH0goCUh2FXx_KgmkEDUxqJUlea5xm3woXEBzx4EQ7UU87yPoHPGM9nHKrufKhUE7NmKUrrf5RC17XfUmAI2tzStdLv7gnfeBQQibEXLfZs8UEPkaoydqiGhodqodepn-p8_TDMVu6sKaIyARPhWDoHuYtvKD2zRzTBQIMFSeMjkxFCoXR1dsABEMuiJLeQL61EmFp4zEIznxHng-GqbgFYWcSIjO1DKXRaEC_lewNeL-OpUTbZbncQs-FBRohJrfHbcYuvI_unEyXLSlJoznCLK70DtrmZwN0QoCLu_DE9rUOCy1SEuplBe2qP1TTESLKLiNuKxN0R_5gOpYWzl93VbC4C7HcMbCqd27yoOiDVO6OoDj8MdFywD5aBi-ZuZWClbdvw_zoOMjn-tdFd4VJiCaBryqPba4oxLUCCum_eHw919aG1f4bW3LAz2bEVhJoOJAzusYQv3_2cQFzWlXfJKiViJKbBmBHNhpemTK7htMqWtn6mF3QQwHjCLVJxqeWTzl8GP112t3STgwNrfyOTWpJGF7Jq2OePr-eX_2sVKvLS6aeeHHAyp4vJqw5e8GVYzHnSlrVL5X0VCbKeHkeV8UDawOIJrL7SFXpZdvO9b5y6iO6lu-rtVhyRg34LaJvSzwvCYTOWkfqegy0OOCI2koD2aHLJrdAW51v1bk6NgkfX55qqWIbP0EUjdNFM1t1_DKOwdMtu2A7Lyz8I91vDJLHIIAxQnMeb2dUNUEqvf4sUNsqBxy2YlayYKcKnXiWgPaJ55zWjAgyWx63oHORecs0ZHaGkdQN-aIfYeuwLr2uvwoy1LyX_kY729e5f0369-i6hj0rdRNLVfYuuWGU17t9DQoIcxV7LDrFLQXlhBrivaCCaXSiuR3SJ0tvmHQKjVCa_NVII19ABiulcRtZ8hmvIkDUQhdaJGeHvLF9vizVYdbai-r21oF1iVpOlruTp7pBda8arPyei19ioB1bqmGUs3_xigpC1D8BKYiQWxcucLlUf0Kdms8zZ7B4isVp8JGo1irsW_rfYoffnU3yVRn8d37_z-s1D_sEOIrVJDaKUbqZA5aCo5UFct6wt6X0wii04xm5ie2bRuoIXSVqYm6S8uJkddmcR4gHI7p2vQeRr-5LN9XwI9-Y7ZZa7O4PbS1B8KejfuPfmrXORq9KSPdYXWw459GZvoSvVIV7xCXgFEIGXssxP5VxkWatGhEiNZO6JBN4FZnqlufoY4xHvoFQvgWrukYmqN8ovAA-wKKfBA9EFqevOrn-6cgZHqP5Bnt9kJLXNQ9KMXRAbjEjDMEdl-iybPyPcQeMWTzwrydn0iRniilIJOBbEzafLc1a3gkDomG4Qj5BdfN7xpLQ-s3wuZn-VRfOiJwRefkM2j7R3rcW) in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. In September 2024, the Company submitted a De Novo medical device application to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024. In November 2024, the Company received its Medical Device Single Audit Program (MDSAP) certification and submitted its Medical Device License (MDL) application to Health Canada. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively.\n\nThe Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company’s website at [www.cytosorbents.com](https://www.globenewswire.com/Tracker?data=dgm87mzc4jyBtOpAZVnnIN4PEi3-djudCwnJgpEAeKCRGi10__0vIDCAkgn8y-gftbFzUEzo2liqMiauvapG5tH6FRE5ShQNx9beprb3NOg=) or follow us on [Facebook](https://www.globenewswire.com/Tracker?data=G3oRGxBhfiFPmLUsjcVGL8jlYEQG6W0HTsdPocI8SiXWA0MJe3Hvofli_udbELx0r4QZZMxra6NV1F26LuxMBGHWwOSlcHHXCaTBZsvvIvo=) and [X](https://www.globenewswire.com/Tracker?data=J63A-VQ05466B63gAepMDxYuy4PjbLOQJr7nxYTpkGqXXscU1eYQzXI4MpTwjMzX81f0cqY-tFZg7OX3Scc4OA==). \n\n**CytoSorbents Forward-Looking Statements**\n\nThis press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.\n\n**CytoSorbents Company Contact:** Peter J. Mariani, Chief Financial Officer305 College Road EastPrinceton, NJ 08540[pmariani@cytosorbents.com](https://www.globenewswire.com/Tracker?data=9vegDrioiUb0r2EZLwVqbc4LOsVrPgCCvDjba28y9ssGb2fy1lJmnx-LzjkoioU4xgQQNeEWU4y0jovvRj-_qVO2WbSGe1Kg7X-q1sPksGop7cl7PF0X5z81Ur4NYEJw)\n\n**CytoSorbents Investor Relations Contact:** Aman Patel, CFA ICR-Westwicke [ir@cytosorbents.com](https://www.globenewswire.com/Tracker?data=zfrp5GwQSyO0RdMut7JdT-1gB8QL_-vM11UsR7WgXzHy9vcpOZqjXnEx3Yeh0JlU_X1HHSsgRO-ijo3ksLug6uGREUpU8D8pmC5oAlgzg3U=)\n\n**Converge Biotech Media Contact** Mr. Eswar Teja, Product Manager+91 99485 12050\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3MDk5NiM2NTc1MTc2IzIwMjg2MTU=)![](https://ml.globenewswire.com/media/ZjM5NGE2YzYtN2ZmYy00MDJhLTllZmUtNzA4MmY3OTQ2OWIyLTEwNDAwMTk=/tiny/CytoSorbents.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/7d55186f-ce46-45ab-b1c2-fd0c843890aa/small/logo-1200x628-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/7d55186f-ce46-45ab-b1c2-fd0c843890aa)\n\nSource: CytoSorbents\n\n  * [Print Page![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/print-regular.svg)]()\n  * [Email Alerts![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/envelope-regular.svg)](/email-alerts)\n  * [RSS Feeds![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/rss-solid.svg)](/rss-feeds)\n  * [Contact IR![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/users-medical-regular.svg)](/contact-ir)\n\n\n\nRequest Email Alerts\n\n[](#)\n"
        },
        {
          "title": "CytoSorbents Reports Third Quarter 2024 Financial and Operational Results",
          "url": "https://ir.cytosorbents.com/news-releases/news-release-details/cytosorbents-reports-third-quarter-2024-financial-and",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![CytoSorbents Home Icon](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/logos/Home_Icon.svg) ![CytoSorbents logo](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/logos/CytoSorbents_Logo.svg) ](https://cytosorbents.com/)\n\n  * [Overview](/investor-relations)\n  * [Press Releases](/press-release)\n  * [Financial Results](/financial-results)\n  * [Events & Presentations](/events-presentations)\n  * [Stock Quote](/stock-quote)\n  * [Analyst Coverage](/analyst-coverage)\n  * [SEC Filings](/sec-filings)\n  * [Investor FAQ](/investor-faq)\n  * [Corporate Governance](/corporate-governance)\n\n\n\n# Press Release Details\n\n« [Back](#)\n\n## \n\nCytoSorbents Reports Third Quarter 2024 Financial and Operational Results\n\nNov 07, 2024 \n\n| \n\n[PDF Version](/node/11996/pdf)\n\nPRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- [CytoSorbents Corporation](https://www.globenewswire.com/Tracker?data=Q2TRO2D5X4LTV15eSNwm2tdC1eurirD-pLyDvSyMNNb5PRYNBTYJQbyxvrTXSJDNd8eWLU32ourp5DfNxdme4xzZwyO15WNMrII60zkjtmM=) (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported unaudited financial and operating results for the third quarter ended September 30, 2024.\n\n**Third Quarter 2024 Financial Results**\n\n  * Product revenue of $8.6 million, 11% growth versus $7.8 million in Q3 2023\n  * Total revenue of $9.4 million inclusive of product and grant revenue, 7% growth versus $8.8 million in Q3 2023\n  * Product gross margins decreased to 61%, compared to 72% in Q3 2023, reflecting the impact of a planned production slowdown to rebalance inventory and a short-term manufacturing issue that is now resolved\n  * Net loss of $2.3 million or $0.04 per share, compared to net loss of $9.2 million or $0.21 per share in Q3 2023\n  * Adjusted net loss improved to $4.5 million or $0.08 per share, compared to an adjusted net loss of $6.0 million or $0.14 per share in Q3 2023\n  * Adjusted EBITDA loss improved to $3.6 million compared to a loss of $5.6 million in Q3 2023\n  * Total cash, including cash, cash equivalents, and restricted cash of $12.2 million, compared to $14.9 million at the end of Q2 2024, reflecting an improvement of cash used in the quarter of $2.7 million compared to $5.0 million used in Q2 2024\n\n\n\n“I am pleased with the progress we made this quarter. Our topline performance is a testament to the improving strength of our critical care and cardiac surgery businesses, driven by solid execution from our direct sales team and distributor network. In addition, our manufacturing is now running smoothly with an expected return to more normalized production levels and product gross margins in the fourth quarter of this year.” stated **Dr. Phillip Chan, Chief Executive Officer of CytoSorbents**. “Meanwhile, we believe that we have significantly improved our operating metrics and continue to demonstrate a disciplined approach to cash management. We believe this will enable us to scale our business effectively with improved operating leverage as we prepare for the commercial launch of DrugSorb™-ATR in North America, if approved, and position ourselves for the next phase of growth.”\n\n**Advancing Our DrugSorb-ATR Regulatory and Commercial Strategy**\n\n**Dr. Chan continued,** “The potential expansion of our markets to the U.S. and Canada with DrugSorb-ATR could be game-changing. With the steady growth in our CytoSorb business driving leverage in our operations, we have been diligently executing on our regulatory strategy for DrugSorb-ATR with the U.S. Food and Drug Administration (FDA) and Health Canada.” We have:\n\n  * Submitted our DrugSorb-ATR De Novo application to the U.S. FDA on September 27, 2024, and announced FDA acceptance and initiation of substantive review of our application on October 22, 2024, which is also eligible for priority review based on FDA Breakthrough Device Designation\n  * Received Medical Device Single Audit Program (MDSAP) certification on November 1, 2024, a key regulatory milestone that certifies compliance of our quality management system with the standard regulatory requirements of Canada, the U.S., Brazil, Japan, and Australia. Importantly, U.S. FDA accepts MDSAP certification and audit reports in lieu of their own routine Agency inspections, if required\n  * Submitted our Medical Device License (MDL) marketing application to Health Canada on November 1, 2024, concurrent with MDSAP certification – a requirement for submission\n\n\n\n**Dr. Chan continued,** “These are key milestones that give us visibility on regulatory decisions by FDA and Health Canada expected next year. We are confident that DrugSorb-ATR has the ability to transform the current standard of care in patients with acute coronary syndromes (ACS) treated with the blockbuster blood thinner Brilinta® (ticagrelor, AstraZeneca) by enabling safe and timely CABG surgery while eliminating treatment delays that expose patients to additional risk and consume valuable hospital resources. In doing so, we believe DrugSorb-ATR represents a winning solution for patients, surgeons, and hospitals.\n\nThe potential North American DrugSorb-ATR total addressable market (TAM) in patients undergoing CABG surgery on Brilinta® currently exceeds an estimated $300 million. Brilinta® already enjoys a dominant market share in Canada due to ACS treatment guidelines and is growing in dominance in the U.S. The TAM is expected to grow to well over $600 million once Brilinta® becomes generic and DrugSorb-ATR makes it the only reversible orally administered antiplatelet drug; and with potential label expansion to include other blood thinner categories including direct oral anticoagulants and direct thrombin inhibitors that could make DrugSorb-ATR an “all-in-one” countermeasure for these agents. We further estimate that broadening the use of DrugSorb-ATR to remove blood thinners in non-CABG cardiac surgeries, off-pump CABG surgeries, or in other types of non-cardiac surgeries could expand the total addressable market to $1-2 billion.\n\nAlthough these are certainly large markets, be assured that we have had years of both manufacturing and commercialization experience in our core international markets and are actively preparing to leverage this experience for our expected North American launch.”\n\n**Dr. Chan concluded,** “We believe we have a simple and compelling value proposition. Our North American DrugSorb-ATR opportunity is significant, and leverages the experience of our international CytoSorb business which continues to grow across 76 countries and is generating nearly $34 million in trailing 12-month product sales at approximately 70% gross margins, and is nearing cash flow breakeven. CytoSorb is generating exciting clinical data through our STAR (**S** afe and **T** imely **A** ntithrombotic **R** emoval) and critical care COSMOS (**C** yt**OS** orb Treat**M** ent **O** f Critically Ill Patient**S**) registries with results presented at major scientific congresses. We are also witnessing a lot of enthusiasm for our new PuriFi® hemoperfusion pump, launched at the end of the second quarter 2024, with now many pump placements and evaluations ongoing. Our global team is executing on our strategy and positioning us well for this next stage of growth.”\n\n**About DrugSorb-ATR** The goal of DrugSorb-ATR, an investigational medical device, is to reduce the severity of perioperative bleeding in patients on ticagrelor (Brilinta®, AstraZeneca) undergoing coronary artery bypass graft (CABG) surgery. Ticagrelor is a blood thinning drug frequently administered in the hospital to patients suffering a heart attack. If patients are not eligible for a coronary stent, they will often require CABG surgery to restore blood flow to heart muscle. Current guidelines recommend the delay of surgery by three to five days to allow “washout” or natural elimination of the drug to reduce the high risk of serious and potentially fatal perioperative bleeding from the use of the blood thinner. We believe that DrugSorb-ATR represents a breakthrough solution that will allow patients to proceed with their much-needed CABG surgery in a safe and timely manner rather than risking serious, potentially life-threatening complications and consuming costly hospital resources while waiting in the hospital for multiple days for ticagrelor to be naturally eliminated from their system.\n\n**Q3 2024 Earnings Conference Call** The Company will conduct its third quarter 2024 results call today at 4:30 p.m. Eastern time. Investors interested in participating in the call by phone may do so by dialling (800) 715-987, passcode 9258825. Those interested in listening to the conference call live via the internet may do so by utilizing the following link [https://edge.media-server.com/mmc/p/e9gv3iaw](https://www.globenewswire.com/Tracker?data=v2KMGric2O7RIntECEnBNWIhsBykijKZQqUM7wCBvOvCcEYzxwTA3J3b6h7KLK_OTW96CBRyLkKqIbzCVVLwtitNSE4qFbXq7T6WsD0MJE5-vCGiEqzJleaQOJTyWL9ZDOwURFJ_3tANb2av-8jGeliNU9TBnZxrEqM_yxy3L-E=), conference ID: 9258825. It is recommended that participants dial in approximately 10 minutes prior to the start of the call. An archived recording of the conference call will be available under the Investor Relations section of the Company’s website at [https://ir.cytosorbents.com/](https://www.globenewswire.com/Tracker?data=v2KMGric2O7RIntECEnBNYyK8lznchgssfwJuvrXGijiGTX1F89BKkvUEuWrgxwyfItzaL5XIM6P7-IfiRGTZn8EcgR94sszUVzhxXkhVCRcv8vY9fTB4u_HFDQxOClk).\n\n**About Non-GAAP Financial Measures** To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, and Adjusted EBITDA which further excludes non-cash stock compensation expense, and gain or loss of foreign exchange translation. We also use the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or Loss Per Common Share which excludes non-cash stock compensation expense and gain or loss of foreign exchange translation from Net Loss and Net Loss Per Common Share, respectively. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by investors and the analyst community to help them analyze the performance of our business, the Company’s cash available for operations, and the Company’s ability to meet future capital expenditure and working capital requirements.\n\n**About CytoSorbents Corporation (NASDAQ: CTSO)**[CytoSorbents Corporation](https://www.globenewswire.com/Tracker?data=Q2TRO2D5X4LTV15eSNwm2tdC1eurirD-pLyDvSyMNNaWrWAf8myH1wJNVAUHGXrqeUg35TbrHEKkWg6FeTpC1kLMnldewpKh91znesg-p40fRbsFsB0j9Rx-Zy9RHLYjIDcjViE0hZT6Gm5ZlbMR4cTwWOkJcLwn9ouhApjl_UKAkQ-JfbOK8I7uQH7IZK3ctR0CnZOL9ET4ai9YUuLt5ZaYm0UarO3cHx_xTU_3WDSJY02gqOKMrfz2i3DDSPfnw7W5sMd_cLTSAig8vkeLo6Kfhs6bpYDbZrwBRnrloU34WRCZ9V0Q-A_NwuRMrEkiVBpYln9tayfYhSNuihFWXuf8Ldc_PN5quoCow7Z4vHpJmGbo9Y-UQBJF3L6PLeNkhA6MVa7c1ifpaNSRf7OddOSLoigcsVVJ-9rfaTUBwiatWuG-CdOQ11SOKp60A9WG3eluneYxx5GWpF1x6RcD_ax5NizfIxr6NmO0TeVCnABIOyTcYOSS3HYosSya6kV0) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, ECMO, heart-lung machines). CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.\n\nCytoSorbents’ lead product, [CytoSorb®](https://www.globenewswire.com/Tracker?data=Q2TRO2D5X4LTV15eSNwm2pr96KWAdGSoBjEGRMpVBCaNaUW_JCCL3n2x39hGiXkkjSVPvEsfMLM9g-R3PB_ybw==), is approved in the European Union and distributed in 76 countries worldwide, with more than a quarter million devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for [ticagrelor](https://www.globenewswire.com/Tracker?data=9Hd1k8czApat7JsVgQgetR49tajVOMBN_I5Zora0rql-u7mcy8UF-z1GifJTf5U6eUN_gPZS6U7W8e3-SsEdO0gM1AAl7xaMn9s6qYCswfS3-iyTR6oiIIBtU1n8wS0WB9Ihh1Uajq_eXMyd7ZOjot_S_74nTdh6-3j1wnJBXKNA4e2ao4uK6sYkzMX5XIEIRnIG3MjxWPFh-a4zqBU3planwOunq-KF0nhIzVR-FHzKueatd72NjGjMyjucA80KbfZ0XkFcfBKOOuQmI8ILH6_6OyecV5751UJnp_EKtTLBwJpQc_ABtzvF7XCLLcmHDerynNQjE5RtYP2r9lpzhve4iqINMoCVnGpeic6YwnIJAGBs8UU_ArY7t7hWnde_IxvmrJvLgv0kLP5nIX4-SDTgjABNuoLLOhnniX0bk_oALdsAdjLE1BShFVg0laMWzgBiCK4DrxeC_Fi7zc1gacn38p8j82SdwRMP4zIp4esrdVEIUKrMDKKjjG6iBwFHciH4gx7zJ6vjE5ognRPk1YpMVWsn0zG4IXguJMj3G3aWp3olorToSNHHSIOogN46MGeMSNv0USf1Wze8zOx3XrcWMkr9y9RmGXAYPrxo-r5-xb6Dvfqv1_sgMlAlMvJsgfA0CIPwu3MbnqyNqJ-SE0P3IpUOkPbA1TBjv7da57_tXpep_VL2Ks0n-kfO97yReN80yyhWzszcHRdg_AuBd_Yqv1DPWstHfpgf5xXI_6hzLukuOPKEY_aXFD0y9HsCPiZsz8aNkkGTkXMLKrSYoJxURVZN5zXsJzocE1GUZXROCZLtMMokrzNQyKT6Qk8blj-pBgM7r-NfwNxr8dRlMytGAmsUo8v1isUmB1TOZgrmTFYuBks1iv_0TuR2O2-QbBowpcLRpLtdSV4Gn6f6OU1s1u8WhmILD_58nqs2Y0t1GyNJZ61MEtPfrQv7TN2JyWXH89B9x7x9MvbZHovkXujtE74HSuax55AEHMovyUDkeODW2ua7mJ6Jj2egwnbyqzoIpFgXkAQso47qn5C38VnR6CxicEl3S0-M5mIMcBu9AQePOKqWqNMSd9xmnJMvl--BOgaWvm1y_FzGSjH-Z1J5JuUICFA0wP7YvaPJDmwkh2OyBL1OG2rx08GdTn6TyQXRdCwsSI9vFo7uE6_MdA==) and [rivaroxaban](https://www.globenewswire.com/Tracker?data=5UfR__pByZDNfkYh8Z55kL_Z1ga6TNSzBO4ISMLD3akeUPw_peiYF0HKftIVKpk-7NyGHSd63Rmv9IplW24fyuHGQulT3I6mavl4RThYJG79cbbPOnDzeYywm8Cxp1whb40oSvcdPqaL8PvdBxJAJJoH5lQzdN67kTRttcoCAMAFUQ7yBbiUnQ8sRVeVk7PVWyqklcWv74vXOedrGWIDiRuV-z0Vtq_K6tq8DsOnbRDsXvePJZjlu32kTgvWHoLcy5krp3Va1pQfvhtABgJON_ATwcuf45bsFa9A9TnldhkNEKrbWeL9xfT6DsGr5bDIlCbVYT2-LebJmcSy78b1kXdKEdI7FQWnNQAgx0quCMvEqzcgsFjO4iU-ToW6kV6jnEyBP-oH-V2QsysM6rj-HHBAD4ptLj1yc_p02WrY7a-Dry5NEoI9PIM7g0gac3PrY8b1xtGj-z_Ma5Q0L0VQa0_CLweFx1O5kCl-krEL3pjTN65yO3_cHL7GAyGsNrPQx2tBSqAMJ6ClUlxiWieR2FaNoL42YEpmX_6SJRAxz5Vb9hulIyancATidaEnATu2Yr4WoTsgwY_Rv3-9A5fSi3M62jU0PNpE_uOvdUz_B9mgF3hbBas5u-gDIO9a5pfuWaltDI4U3gta1BROzMmi-xcD1Y7dt1TAXSVmSukA9t2Fff4JcM30yR9M6OxgEvFkMauZ7uDjixNbVe3EPztxhm2Fit_pksyAOdnITsRvJNhpN-YPl-ZBwF_nnhmsph8k8tO_wBp1ErQJany6bz9pw20RvY6_cr0sFU3OoxhTCuvvWJTQxHRGvN5fMSBaPlO8zlgI6TMshvpHXIU1JxiqTISrF5y4u1VrrJz2t7_o5lCuOG-oEjMpo_rH3uKnLw7ZhKLjayNXomLRo9YKyI4IXdedYQyxf3d4BTan6ynNSe85o052UOTQ1GpfjSzrwmIMiAxuaalrG4K46AakAeLPZLzRFf1Mw7L6c_ORILr5qMxP4B-yO4Cas-y6mjAZiDh3WORD68pan_HGQ6lxR7hXgUgV3BvwjhmYYa4JyCromeG7GHR1vS5DPJRIaepFtfFAbCuwyiACVBm5n0z8U3isQgavwxgSRHhINwSvBbQFQN5AQ-vT8wkJ_IeQeLrDHFAJRSV1YGzqwFAjlN8ha9NpY7nQHT1TVm2t2pGH6IViFGGkEqWpQcShHLxtw4iQMk1k) removal in cardiothoracic surgery procedures. CytoSorb has also received [FDA Emergency Use Authorization](https://www.globenewswire.com/Tracker?data=LNChg7t39OH9T_p0iNX658qxxQVw6G8FRnu-23vZmyRCozqjoX3FxM5EcCwMsMorFyaw-U5JsgVpTV0-rEqXFlgKIQwdStj-DisaKSSZHbxKS0u-vqKfWHLB0IO6I0PfdXGB3WU5TaqM1qsx1-MUA3EDyWoRaubQN7j0WVkgaMZm73fw8oiaDGuWnhyHTt0m6UWJY-TBurnPSnzDhTAyXIkExscuhPQ8L-6D1IiXkX5bm3p95XkeZRNaY6IMXJSkAT8Czvib4m_ETHfjcjhL-TOQVGv6GYdMR7ZvJ_Vz_BmIlaIpPQqwBxm4hFoBwxQQcG03Bat5mwVcwh8as9Xkrb-remM97f2D9WqhRHnvKaTyLSSzKHdMC8jfluUJSvRTchmxxk7rIiIGyOdbWD5YlYMtHgBNwnsJ22uaUk7MNpKijuxhZMDxHYf0T-weS-mkCD40EO9HkvFMkxYT2qbE32MrivmyWJX3xtrtZ80ECFBrC8WF9c2f9psWI-WsWQVqgV9teepVmgU7OM_oSU3AIDGIIadXp1sH2Mr6H-1nXjWatfW5-BD78lDUFVUM0qx3r8T7Bth0lL_NJTlkLUFtcMMAN1Hwxkev6KYD0y6VClSNy5P-vcIKeJMbE_Cp8YE2RjUe_mGkKV5bBWEts-bNIIcSFe9Ic9hnhgg0cAj42VkwewHWOvVA4XR253k2vdN7C7RBYuqboeBXzkmP9DcrZKCT03N7aJBQO4CNVFoiuEu74SyalJd4lUgQK6uuG_EYWxVcxkiDEWQ2RDzHyBtk8ZQreDjiSCWB6BRjxKL_iqPZxU9a1GuhdZhqcKDK31EanmAKasUa1bkip0TChQ68kfNaEnB3sHY-Fg6WvzgI6Xt-J9r1-KgC7Dv-9iqS70aCMEYqvHjujVkmdJ_iuz9IQ6tF_gxAGmH8ymKQwjjs0SvNxN0DKgUIMTIoOTJuytqHM1pfPqAYQ7Av5GiPx37DrblSCDPWEnpbHTaNPNI807U7gWOrBSrfZGx1QXvwAI_8VCtZExtdK7OtzKMXGC2fyOZ7j0c0m068SMJcIK1o9OcfZWeVYCrpBQp4Yojw0dLDTTLbC9503mUt-BFoUWw8yRVqmVatZdORlELtSVXjvixh35V_Wyfep54rqtX_Dhu6ZmjoPs68IlIOtKR3KzXSBuUTjNhALr9hHY1D8hxXSfu2aYznFoFMAOUWhmRk8eJ_f8C8kc8tq_mtNoRVl4u7pQRafVdhnbmrK4G5uCbIW90=) in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure, to reduce pro-inflammatory cytokine levels. CytoSorb is not yet approved in the United States.\n\nIn the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two [FDA Breakthrough Device Designations](https://www.globenewswire.com/Tracker?data=P1LZz5ORurpzqs1oX2DPTxjXLPpVnrqwsRNMCn_2QjjktOakzk_pz8NQsJeIP3t4EXcZaXl4RIIS-qPh7NT-jQFtgs-mnwWgiNQPCC149r8-W-fX8PNt7JVunH0BSSWiRbXi1FB4YeuD8VUptEKkYza6Io9WWl8ukvmF8DQV4xXXx7aSyBvaXzMoWTSxB6H_Bq8o7kKc4V-OAdVJgEZBYzsFLHA0a6sbMJox6005mZ1uv8lfY3KLZn0cwVrQ3MyHKfMVL1QoStVAdLiMZPqlh6tWRgvkPehd85-PfHzL9QJkDrRUNF_I23HQVLmfkHU0AVhWPl03i1BX4dxnDU5-ALr5PM-3-9AIc8iVgzKOdbj_UILm_o_RFzMwvhkrxTogB_luppUhkWv8TkUTHoreyIVzmkJxDK03drvl1xhA_sQY9896HUHmlfx5m2oY4Bh2DTTg5CvnCAeZfbHMrDiye1pNmuUjiTZswSJbvlcfY-omGvjRy05_gZgBMUxNZwHnoi7W9_fQofnYIS8n4bxRs80k9BgFA2B5XKjTCR7kmUvvt4V9of6rV8xvYNm4eugqKgahPvnyiDWUdKY-Mgh5ZtMGzCQghkJy1X4n-u_xUR2EcGnKWCFQbYy5csyfZSu1GUUrPoyk7hjsysqjg-TZiXC0KyQjZ9ID7yknXCjx5wqH4zVfkfcB9UE1s93gvvMemPQZ4bjL_BRE6OJ8Hv3aluR6GACQ-D8WCkFvsLjwLyqV1YIbQP1xtKk2Ur65Ls4JKweG7Nkljui9X_DiQAljyUcLQReqeEVfpyP68JF_CEwmUOByFmZQaSFsDOFhZ6FDiwcN9ii-AM8-qwHopkJO7a5nn8a-gnVETMuNu_nPA3GKycF0YmPfnRMFdo8xzdmtET0c0-4Z3Ic7EKxQtXn7NoF0tnUjEivkC4_xfCPDZ2JELeBtcg9J9SOHyIsvv66t16OA4wcgXj6enK_fKum8NLnOlJp-W07rrQGNU0wyRBDpcMOGZIb-I94ow1QbZwP95p2I16FXtcP43fUUuEAXgHmryXKuqPPg9J-H5ACXZbsgMAVfHjevd0Te2kd1ch2krJ2YX0lmVNQhDFJkpoT6RIuotaL1otW113MQZT23HSxfRURk-hiSs5wFEihOeMKKyzPMGxlSfhj7oQnrEc5UFm6EqJfDNkBV7kMpgvdhHobvB_nvcdPQDnj4bDzbpMrY7_qlYE16bIlt5nVtPn3WnDlvQkYKRCAyH2C5sku1gQMIUH9bH5VHESJNQbMRkMedp_h_NhBUgrzYl7BmSb8u5w-wqZ974qg-YPOIZwVuWAsPUR0sQk6OXh0kzVbw23Pff5kJOKMET7lVviOfKk2cbgyd3zZTRapi4RjYD4Ft9K8YCX4kSqgfdjGBkFADPUzxR0XedfqYWNCwXH_7I5RXLDCTzH3XZ555T0eTcFAMAoazYBYzTT28cp8SBRQu3vG_l_nSNA83jZsl7IRIzuMcnt_Rgh4Gt1i0-MnfsUrWKdg=): one for the removal of [ticagrelor](https://www.globenewswire.com/Tracker?data=9Hd1k8czApat7JsVgQgetVkww2m5ibahv35TUlfK_coiVg883xHIOCpz6UbnWD7aj2wduRuoBRSjwmshu77E55WA2KRtizj_J5Jw8QSqeyqzrcIfZyGlzYfO9leIFP_UqHvrO1_0IBjsCQa2aMYm30NIC-Wojttxg1dJq4XqyEnFbBleV3RoUHkgpuHMhh6q7mQFzGmPb5eiGeud7VCx18SiMgMo2z-ffy9_PIM_SyDZ39BOp2JN7dQ_MiS5q8b0N454qRa_nMX6aF49iVZGjK0t50QI9BMnwbt-jKqMQMTOR6QU5roSOdTHd24FWm_VpIaedEnwUf7uqzWF0iVL5ks1mCXmW75Sf5VAV6NP85-ijNywDkgYPmvMaEDfNBaMaeMEwzKAy9gLOvMrLi-l0gRG7O9VqwooMjezShqkG5R0hxW4xZN75_CJ3WfGnoPNuYi0U0HYPklvxT08iFS0fxOEd7XTChy2AoL_emO5vpg8wmeqNdnBi7lDK8lVF4uRJHePlcvP6FfmVT89nvSzX7ECli_sFSb6qicMAoW0Wzo8ARDnny4GDgJKIDVbdpG7X65QQxa2lXacrH1tI3Q20fxC_pyBUJF3jMrh5OAFmav1dV0RtLATVI8wmhmdB5vuUBeTAry5-7JQaCDXT3wAz_ySlH69__nWEJj-VdM3g_ixNN7DauQzLN-j5XHM-A0zXPhu3t2pTLf9tlBX8dMiWeNUEiEGdPWEy0_S3LI81yJY2L1QLoR1JK3vEYMqUZc4kaMtasZFXpDu5-IoJjeObQLrY2zfjzJ6HkojmeIiUWetvcAwff3Jn5nkHZ-OzlosTeuowq9qtxYfIiXOgsc7Zz3rF0y0eo0zITs2ufGjaWyRwal7ow2GxGidNmJKzwY-bBC8PSAEiwTpDC4u5NY3rvklOuLQ8JfeQYKaGX6bmHKHkWp2BCua2AOOIwJ0Sg4xwVbIeG1Z5WcVX9hguZshywM0E4KEQ_YhOIXkVbkZrcT82Fpiq_ZA_KJjHBSXCfg2Ea9SVhp0ldqNirdgIk2VygmGhMbxXv4Yk2_FsoAKoGSH66p6d_I4CO75jc9UO4nAIJbEPKtSAjapeWn8grYDe89rmp5LUPIvtvpvpDbVrNqx1QnliYUT7BBT43UZoSnL0AIsBX7Oa0uGiDXQXFnobSpmQokqBFTuYuqF6BXBXfNguAqN_XXN5O0hr3LWWs2XYWoVVL0pjbwY_SQMm4WUvZGN-k8twD1Di3igCIRPqaBU9vGmdkF6KE8nzcKmC3eawJpRINSS-I19VF2tf-BPT1liM0JOfOhZePySSjtVnbmBBhhMfjZwbwn-RYSommjc) and another for the removal of the [direct oral anticoagulants (DOAC) apixaban and rivaroxaban](https://www.globenewswire.com/Tracker?data=o5kJRJGKGVEmx63y8QWo9ha2aArx2vLYPm1RovSbMus9LfCk3KH05W1jOTeh1gDqtkHHUUSr6Hc6af4lQf_gqtTm-mysZQCmswVXIAcsNNF6oe_UAR-Hip70HbTSje9EsVrWOsLva4iIS_EJWEbT3sj9neGsj3yg2i1sKWrZncbJ-bNaU7E0h5eK1NPqsiuGEMCePrWVaT_NnrgvsdXRFo765bbJ10Fmaq7bpgJZrJrbr4SUSZxfSEyPLe5wsM-xRAkYvw2ERngS_htDAcZA_Y3oqpjLm8RBozRkobWTfCiessY0uscptQ7kcMcUOl_4xWi4EqpVjGrACnsKXRytEHTwE_wHyo6L_nLxvLqdKdqKR8tcL9qFywiBuAFZTWU3WwIz6lMDbEN_VUI6JZUewt_PHrIQvDHRnyySLkrXqGc10Jrul3_naKHzXpc79RSc-Nld0IX7J6DJcomlwk3vG0d7TJ9VJHy8SHS6mSnqwVq7RLC0kn7PwdOvt3Lwdekww9bWACNmdDCznQH09Y3Nd7Y0HmmJBOtzb7LMSUMsG6iHXumTx4URGKgGFvNNeZyUQPtf1dZ61884TKTwdF4EclRZsnPzy2Bz9IVe4w_8xAPwjdTBG3cO_SzbGcPohldLeqG3zOZoucgXqAYpr9mVpOqhiy-9z4hIalkJZo_ZoHxZG4A4evMeZPFhPqmoVVq4dqH74I3gZ3jncnVzpLpj-2aLhHQMh-lqpRzQ7clsKumHH8lbGKr6edV0dkwuSOKa8EDJKKLWypzgd4zaHXkt-x5qB9u8znlsBsVJee31jbRokSmxzQ_P6ULbxFbKZm-G8rb5-H1ZSh_v0zQRPcSNXva8xqxVakGtp9eDjDLyYTk9cvz5erLEdD3WXMGEnzvI-cTn6s1vXiCr3oTNwDfrwZnoK60L6sh_0Hgmf2JPp7fDCtlCqgaROQO5xcBQN85-Xw_2n9jeuIITY93h10gaD-7D9Kh0iuP7gp8n_jQWzFlyvWfYqUYH1z3Hu2JZ1jaAHDKMud1fCNpV-Tp0cYOuHy0J5SoWc-jl1s2ZRfksIxnoQQwCm-t7ZDH_zVNqxiW3Mdcov9RrtEM1YMShVwIvBOaqyxhHwoUcfi910pnTCapi-a1BWteqP2OKDXFgNfO8CXPBtuT5HUg22Lm7thXjSYG_enrTED2swDWAACPStjwrjUKLFTPLMNZXcF5JD670LK7zjGd6N7G6_t3sBSoMqOCN5mL0oNZLF8Ut0o-6CwLmDfeE1tTU_wyML9AJVxWUnJVWwCwrM0VqJMLdermwuZyu7vf2zqozMouY7KEEwkEJOlC5OcV-H-QD-VIafHXKZD4KmPn577sEHWmsLa5Kbj2QCcqlhRU1BeD9LBwUbr6o-IRG82_1fhMkuOwacNi9aXsh-X4H_N1IR1MKKvreDJ5pwOs-kmGp79fe_4cw6F_bNnanSAjg1GE9jNOs-TjY-5e84qgHu2Na5bV5nHy_o1pURm7EI8cFHCKr_gwWS-ON5TywcDIVh5pP37oBnafpqejmTikgED3VeSwKzP-Wd-2-YTbamWOYTY1pPoQ1cAZ9yBtGK6bhhzcSkjEInfqfCqTwmRDTOSO4iJpcaP9eoAM_bvo22644DcrwSoljRDlxfqq1cMdp4vQk6KSZ-b9fAiaPh0M2FyBlLP0dJyQaUxTiVEak_1E4zAxD2SXaEVx-1RhD741Jd1-U3daVlj9mNsTqvKO1s3j-Bkv7k-WTc2OCp6F0pRK_M9piMqIdT_uvULGrb8ad4HBL2i5DH-f_u7hlV0BcIndQORIfmGyb5SnzENWs_lUEwdPn5FGaEaW37S3g31K4Dz5veyaMsLbl) in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. In September 2024, the Company submitted a De Novo medical device application to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024. In November 2024, the Company received its Medical Device Single Audit Program (MDSAP) certification and submitted its Medical Device License (MDL) application to Health Canada. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively.\n\nThe Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company’s website at [https://ir.cytosorbents.com/](https://www.globenewswire.com/Tracker?data=v2KMGric2O7RIntECEnBNYyK8lznchgssfwJuvrXGii6byAspgCqStZDBnFVHIxEjCrC4VAdX4ek9ouRsbHGM4CaUrNhNXeFWl1nPdBD5Cby0n5uCpKZ9gVdgmexn9Un) or follow us on [Facebook](https://www.globenewswire.com/Tracker?data=dNbdiCtXUY9FTWKDpOzhPAoBlrZEDsSEw0pK9e25nDlUnp7q1Au2ZxGNX5llXEhmjFMscHmwZmuJEhQtukt6ZyjutKbaysv50RQLnZlBqi7dlMf6OJ5SDBf_ztPmPnqcmTqtCUQJtsMaNT-oCyZ8T_H_PuIkdMvFEuXU-syIhS5MAUefTbsyTYB9-eAEIUEY23APfSOGOowj_mC8NwydKP9RwOaissXkVXiGtUZkMDS20FmtWcPtBjiE3vxKV4a_lpikpJih3J3Z_0fl5Rv6LldVYuakpEBL1cPJtxcN6UJptPZJMSNl_MXgaT2xMgLqlg2ZJBHBNS8TaZE42MPFHJFJikws2rG55bVW00W_n2WmxVmeWsXrGKCI3hwi6Xof2T1O8EmlWcdVslofDoCsF2oOpMtFj64njozRB3ILJ7QvR_TuEnkumnCBPJXYs-aS) and [X](https://www.globenewswire.com/Tracker?data=SwxlHNRdcJsaY8ic-N1-x1uiV3YCjyENkvd3I-ZmPZpO21dvaSmVBBLF6dHtNPiTBv6BERPOOvVEYYcAC7YPb7wvNH1ENLMe6P25VVF1DFBA2qm10Psyz-OOiutYic5OakSNwtYxDqBMCatcdzoWnyQoo_vrIRqqR32PEZi76pC7Q2s9qsJbRCAzIT5EVCZ9h0aV94CNrMECa_BaxJs9WQG1fCwTSqR9ocgX7MZVJrmgduTgO-5AAyNB8d4F4juG0vV1pA0KystoV_gulBtxhhrueKM6iCjJs4FAIWFaSLKr9p7o_uGd9cGmPU4_RQ0nrQm2S1zuHbEJ--3l-soHl4McfqeJllkLNXfgJ7ABNiC1cD-HnvIB8qVSwMaM3AHJ). \n\n**Forward-Looking Statements** This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.\n\n**Please Click to Follow Us on**[**Facebook**](https://www.globenewswire.com/Tracker?data=dNbdiCtXUY9FTWKDpOzhPIzeIXlUqjf9VmpKuvggswTfsMg8fQnsnj-M37i02rgGAi3CBgUKMk6h9SHJ8XyRwOkEIKJMP5PSjWS2UHkHnKM=)**and**[**X**](https://www.globenewswire.com/Tracker?data=090q__8PZaKnIICR1plNMvk9pxCPhqvc_opIlRu9bCHFP7ojCTnGwsLbAqbkbnnAtayslhFrhYFkhKhHZVa5zQ==)\n\n**U.S. Company Contact:**Peter J. Mariani, Chief Financial Officer305 College Road EastPrinceton, NJ 08540[pmariani@cytosorbents.com](https://www.globenewswire.com/Tracker?data=fVvPw4z85z7m7NX-PYEDsQ0v4T-cYNVA1BgGiIgrqBMqAau7YQpRDPtVuTYUlHDPZ2UAnGebOVmKfw87Kbb1tfd8yRCxjMV1csiLU-HLEGkFdxVTzcpRib0jLsCS_KTZ)\n\n**Investor Relations Contact:** Aman Patel, CFA Investor Relations, ICR-Westwicke (443) 450-4191[ir@cytosorbents.com](https://www.globenewswire.com/Tracker?data=bR4Um2eVF4X_o37aMRO8vZLrw3Q_49R8QRsw7mysv8mkT_jgzIBEmLR44jsmdM8JW00QmFPUjUUY9QciFRCUYfAY2GcRW2dGiWnvpILTHLw=)\n\n**CYTOSORBENTS CORPORATION****CONSOLIDATED BALANCE SHEETS**  \n---  \n**September 30 ,**  \n**2024** | **December 31 ,**  \n**(Unaudited)** | **2023**  \n**ASSETS**  \nCurrent Assets:  \nCash and cash equivalents | $ | 5,685,328 | $ | 14,131,137  \nGrants and accounts receivable, net of allowance of $160,246 as of September 30, 2024 and $49,663 at December 31, 2023 | 6,632,590 | 6,057,072  \nInventories | 3,247,756 | 3,680,129  \nPrepaid expenses and other current assets | 1,031,694 | 1,834,485  \n**Total current assets** | 16,597,368 | 25,702,823  \nProperty and equipment, net | 9,269,899 | 10,056,354  \nRestricted cash | 6,483,958 | 1,483,958  \nRight-of-use assets | 11,651,563 | 12,058,896  \nOther assets | 3,801,223 | 3,958,603  \n**Total Assets** | $ | 47,804,011 | $ | 53,260,634  \n**LIABILITIES AND STOCKHOLDERS’ EQUITY**  \nCurrent Liabilities:  \nAccounts payable | $ | 2,338,143 | $ | 3,802,170  \nCurrent maturities of long-term debt | --- | 2,500,000  \nLease liability – current portion | 431,997 | 373,636  \nAccrued expenses and other current liabilities | 5,660,051 | 7,870,149  \n**Total current liabilities** | 8,430,191 | 14,545,955  \nLease liability, net of current portion | 12,568,745 | 12,896,659  \nLong-term debt | 13,805,985 | 2,542,857  \n**Total Liabilities** | 34,804,921 | 29,985,471  \nCommitments and Contingencies (Note 6)  \n**Stockholders’ Equity:**  \nPreferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023 | — | —  \nCommon Stock, Par Value $0.001, 100,000,000 shares authorized; 54,500,613 and 54,240,265 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 54,498 | 54,240  \nAdditional paid-in capital | 308,441,887 | 305,196,874  \nAccumulated other comprehensive income | (156,925 | ) | 529,321  \nAccumulated deficit | (295,340,370 | ) | (282,505,272 | )  \n**Total Stockholders’ Equity** | 12,999,090 | 23,275,163  \n**Total Liabilities and Stockholders’ Equity** | $ | 47,804,011 | $ | 53,260,634  \n  \nSee accompanying notes to consolidated financial statements**.**\n\n**CYTOSORBENTS CORPORATION****CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**  \n---  \n**Three months ended September 30,** | **Nine months ended September 30,**  \n**2024** | **2023** | **2024** | **2023**  \n**(Unaudited)** | **(Unaudited)** | **(Unaudited)** | **(Unaudited)**  \nRevenue:  \nCytoSorb sales | $ | 8,586,274 | $ | 7,709,085 | $ | 26,381,455 | $ | 23,681,183  \nOther product sales | 26,521 | 44,931 | 62,649 | 55,285  \nTotal product sales | 8,612,795 | 7,754,016 | 26,444,104 | 23,736,468  \nGrant income | 777,593 | 1,056,831 | 2,627,212 | 3,944,696  \nTotal revenue | 9,390,388 | 8,810,847 | 29,071,316 | 27,681,164  \nCost of revenue | 4,108,773 | 3,203,981 | 10,716,394 | 10,600,421  \nGross profit | 5,281,615 | 5,606,866 | 18,354,922 | 17,080,743  \nOther expenses:  \nResearch and development | 1,851,230 | 3,749,197 | 5,619,040 | 11,632,416  \nLegal, financial and other consulting | 823,914 | 1,103,475 | 2,325,351 | 2,957,738  \nSelling, general and administrative | 7,002,718 | 8,104,392 | 23,151,118 | 24,358,417  \nTotal expenses | 9,677,862 | 12,957,064 | 31,095,509 | 38,948,571  \nLoss from operations | (4,396,247 | ) | (7,350,198 | ) | (12,740,587 | ) | (21,867,828 | )  \nOther income (expense):  \nInterest income (expense), net | (588,153 | ) | (33,670 | ) | (774,903 | ) | (105,662 | )  \nGain (loss) on foreign currency transactions | 2,650,309 | (1,809,652 | ) | 680,392 | (733,997 | )  \nMiscellaneous income (expense) | — | — | — | 35,000  \nTotal other income (expense), net | 2,062,156 | (1,843,322 | ) | (94,511 | ) | (804,659 | )  \nLoss before benefit from income taxes | (2,334,091 | ) | (9,193,520 | ) | (12,835,098 | ) | (22,672,487 | )  \nBenefit from income taxes | — | — | — | —  \nNet loss attributable to common stockholders | $ | (2,334,091 | ) | $ | (9,193,520 | ) | $ | (12,835,098 | ) | $ | (22,672,487 | )  \nBasic and diluted net loss per common share | $ | (0.04 | ) | $ | (0.21 | ) | $ | (0.24 | ) | $ | (0.52 | )  \nWeighted average number of shares of common stock outstanding | 54,453,006 | 44,373,969 | 54,340,583 | 44,024,483  \nNet loss | $ | (2,334,091 | ) | $ | (9,193,520 | ) | $ | (12,835,098 | ) | $ | (22,672,487 | )  \nOther comprehensive income (loss):  \nForeign currency translation adjustment | (2,330,743 | ) | 1,655,674 | (686,246 | ) | 654,792  \nComprehensive loss | $ | (4,664,834 | ) | $ | (7,537,846 | ) | $ | (13,521,344 | ) | $ | (22,017,695 | )  \n  \nSee accompanying notes to consolidated financial statements.\n\n**CYTOSORBENTS CORPORATION****CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY****For the three and nine months ended September 30, 2024 and 2023 (Unaudited)**  \n---  \n**Accumulated**  \n**Additional** | **Other**  \n**Common Stock** | **Paid-In** | **Comprehensive** | **Accumulated** | **Stockholders’**  \n**Shares** | **Par value** | **Capital** | **Income (Loss)** | **Deficit** | **Equity**  \nBalance at June 30, 2024 | 54,306,415 | $ | 54,306 | $ | 307,514,758 | $ | 2,173,818 | $ | (293,006,279 | ) | $ | 16,736,603  \nStock-based compensation - employees, consultants and directors | — | — | 781,881 | — | — | 781,881  \nOther comprehensive loss: foreign translation adjustment | — | — | — | (2,330,743 | ) | — | (2,330,743 | )  \nATM Activation Fees | — | — | (41,444 | ) | — | — | (41,444 | )  \nIssuance of restricted stock units | 194,198 | 192 | 186,692 | — | — | 186,884  \nNet loss | — | — | — | — | (2,334,091 | ) | (2,334,091 | )  \nBalance at September 30, 2024 | 54,500,613 | $ | 54,498 | $ | 308,441,887 | $ | (156,925 | ) | $ | (295,340,370 | ) | $ | 12,999,090  \nBalance at December 31, 2023 | 54,240,265 | $ | 54,240 | $ | 305,196,874 | $ | 529,321 | $ | (282,505,272 | ) | $ | 23,275,163  \nStock-based compensation - employees, consultants and directors | — | — | 2,344,671 | — | — | 2,344,671  \nOther comprehensive loss: foreign translation adjustment | — | — | — | (686,246 | ) | — | (686,246 | )  \nIssuance of common stock offerings, net of fees | 53,290 | 53 | 11,741 | — | — | 11,794  \nWarrants Issued in connection with long term debt | — | — | 690,709 | — | — | 690,709  \nIssuance of restricted stock units | 207,058 | 205 | 197,892 | — | — | 198,097  \nNet loss | — | — | — | — | (12,835,098 | ) | (12,835,098 | )  \nBalance at September 30, 2024 | 54,500,613 | $ | 54,498 | $ | 308,441,887 | $ | (156,925 | ) | $ | (295,340,370 | ) | $ | 12,999,090  \n  \n**Accumulated**  \n---  \n**Additional** | **Other**  \n**Common Stock** | **Paid-In** | **Comprehensive** | **Accumulated** | **Stockholders’**  \n**Shares** | **Par value** | **Capital** | **Income (Loss)** | **Deficit** | **Equity**  \nBalance at June 30, 2023 | 44,193,696 | $ | 44,193 | $ | 290,199,035 | $ | 1,328,313 | $ | (267,476,845 | ) | $ | 24,094,696  \nStock-based compensation - employees, consultants and directors | — | — | 1,086,163 | — | — | 1,086,163  \nOther comprehensive loss: foreign translation adjustment | — | — | — | 1,655,674 | — | 1,655,674  \nIssuance of common stock offerings, net of fees | 162,078 | 162 | 632,232 | — | — | 632,394  \nProceeds from exercise of stock options for cash | 7,962 | 9 | 15,920 | — | — | 15,929  \nIssuance of restricted stock units | 74,773 | 75 | 220,211 | — | — | 220,286  \nNet loss | — | — | — | — | (9,193,520 | ) | (9,193,520 | )  \nBalance at September 30, 2023 | 44,438,509 | $ | 44,439 | $ | 292,153,561 | $ | 2,983,987 | $ | (276,670,365 | ) | $ | 18,511,622  \nBalance at December 31, 2022 | 43,635,715 | $ | 43,635 | $ | 287,000,021 | $ | 2,329,195 | $ | (253,997,878 | ) | $ | 35,374,973  \nStock-based compensation - employees, consultants and directors | — | — | 2,486,679 | — | — | 2,486,679  \nOther comprehensive income: foreign translation adjustment | — | — | — | 654,792 | — | 654,792  \nIssuance of common stock offerings, net of fees | 590,348 | 591 | 2,106,528 | — | — | 2,107,119  \nProceeds from exercise of stock options for cash | 82,355 | 83 | 213,224 | — | — | 213,307  \nIssuance of restricted stock units | 130,091 | 130 | 403,811 | — | — | 403,941  \nLegal/audit fees related to ATM offering | — | — | (56,702 | ) | — | — | (56,702 | )  \nNet loss | — | — | — | — | (22,672,487 | ) | (22,672,487 | )  \nBalance at September 30, 2023 | 44,438,509 | $ | 44,439 | $ | 292,153,561 | $ | 2,983,987 | $ | (276,670,365 | ) | $ | 18,511,622  \n  \nSee accompanying notes to consolidated financial statements.\n\n**CYTOSORBENTS CORPORATION****RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES****For the three and nine months ended September 30, 2024 and 2023 (Unaudited)**  \n---  \n**Three Months Ended** | **Nine Months Ended**  \n**Sep****30,** | **Sep****30,** | **Sep****30,** | **Sep****30,**  \n**2024** | **2023** | **2024** | **2023**  \n(In thousands, except per share amounts)  \n**Net** **loss** | $ | (2,334 | ) | $ | (9,194 | ) | $ | (12,835 | ) | $ | (22,672 | )  \nDepreciation and amortization expense | 381 | 402 | 1,180 | 1,062  \nIncome tax expense (benefit) | -- | -- | -- | --  \nInterest expense (income) | 588 | 34 | 775 | 106  \n**EBITDA** **-** **non** **GAAP** | $ | (1,365 | ) | $ | (8,758 | ) | $ | (10,880 | ) | $ | (21,505 | )  \nNon cash stock-based compensation expense | 458 | 1,372 | 2,220 | 2,667  \n(Gain)/Loss on foreign currency translation | (2,650 | ) | 1,810 | (680 | ) | 734  \n**Adjusted** **EBITDA** **-** **non** **GAAP** | $ | (3,557 | ) | $ | (5,576 | ) | $ | (9,341 | ) | $ | (18,103 | )  \n**Net** **loss** | $ | (2,334 | ) | $ | (9,194 | ) | $ | (12,835 | ) | $ | (22,672 | )  \nNon cash stock-based compensation expense | 458 | 1,372 | 2,220 | 2,667  \n(Gain)/Loss on foreign currency translation | (2,650 | ) | 1,810 | (680 | ) | 734  \n**Adjusted** **net** **income** **(loss)** **-** **non** **GAAP** | $ | (4,526 | ) | $ | (6,012 | ) | $ | (11,296 | ) | $ | (19,271 | )  \n**Weighted** **average** **common** **shares** **outstanding** **basic** **and diluted** | 54,453,006 | 44,373,969 | 54,340,583 | 44,024,483  \n**Loss** **per** **common** **share** **—** **basic** **and** **diluted** | $ | (0.04 | ) | $ | (0.21 | ) | $ | (0.24 | ) | $ | (0.52 | )  \nNon cash stock-based compensation expense | $ | 0.01 | $ | 0.03 | $ | 0.04 | $ | 0.06  \n(Gain)/Loss on foreign currency translation | $ | (0.05 | ) | $ | 0.04 | $ | (0.01 | ) | $ | 0.02  \n**Adjusted** **net income** **(loss) per** **common share** **- basic** **and**  \n**diluted** **-** **non** **GAAP** | $ | (0.08 | ) | $ | (0.14 | ) | $ | (0.21 | ) | $ | (0.45 | )  \n  \n**CYTOSORBENTS CORPORATION****HISTORICAL RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES****For Year-ended Dec 31, 2023**  \n---  \n**Mar 31 ,** | **June 30 ,** | **Sep****30,** | **Dec 31****,** | **Full Year**  \n**2023** | **2023** | **2023** | **2023** | **2023**  \n(In thousands, except per share amounts)  \n**Net** **loss** | $ | (7,326 | ) | $ | (6,153 | ) | $ | (9,194 | ) | $ | (5,835 | ) | $ | (28,507 | )  \nDepreciation and amortization expense | 258 | 402 | 402 | 397 | 1,459  \nIncome tax expense (benefit) | -- | -- | -- | (814 | ) | (814 | )  \nInterest expense (income) | 63 | 9 | 34 | 52 | 158  \n**EBITDA** **-** **non** **GAAP** | $ | (7,005 | ) | $ | (5,742 | ) | $ | (8,758 | ) | $ | (6,200 | ) | $ | (27,704 | )  \nNon cash stock-based compensation expense | 1,080 | 215 | 1,372 | 1,053 | 3,720  \n(Gain)/Loss on foreign currency translation | (661 | ) | (415 | ) | 1,810 | (2,683 | ) | (1,949 | )  \n**Adjusted** **EBITDA** **-** **non** **GAAP** | $ | (6,585 | ) | $ | (5,942 | ) | $ | (5,576 | ) | $ | (7,830 | ) | $ | (25,933 | )  \n**Net** **loss** | $ | (7,326 | ) | $ | (6,153 | ) | $ | (9,194 | ) | $ | (5,835 | ) | $ | (28,507 | )  \nNon cash stock-based compensation expense | 1,080 | 215 | 1,372 | 1,053 | 3,720  \n(Gain)/Loss on foreign currency translation | (661 | ) | (415 | ) | 1,810 | (2,683 | ) | (1,949 | )  \n**Adjusted** **net** **income** **(loss)** **-** **non** **GAAP** | $ | (6,906 | ) | $ | (6,354 | ) | $ | (6,012 | ) | $ | (7,465 | ) | $ | (26,736 | )  \n**Weighted** **average** **common** **shares** **outstanding** **basic** **and diluted** | 43,676,435 | 44,015,380 | 44,373,969 | 46,531,510 | 44,656,391  \n**Loss** **per** **common** **share** **—** **basic** **and** **diluted** | $ | (0.17 | ) | $ | (0.14 | ) | $ | (0.21 | ) | $ | (0.13 | ) | $ | (0.64 | )  \nNon cash stock-based compensation expense | $ | 0.02 | $ | 0.00 | $ | 0.03 | $ | 0.02 | $ | 0.08  \n(Gain)/Loss on foreign currency translation | $ | (0.02 | ) | $ | (0.01 | ) | $ | 0.04 | $ | (0.06 | ) | $ | (0.04 | )  \n**Adjusted** **net income** **(loss) per** **common share** **- basic** **and**  \n**diluted** **-** **non** **GAAP** | $ | (0.16 | ) | $ | (0.14 | ) | $ | (0.14 | ) | $ | (0.16 | ) | $ | (0.60 | )  \n  \n**CYTOSORBENTS CORPORATION****HISORICAL RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES****For year to date, 2024 (Unaudited)**  \n---  \n**QTD ENDED** | **YTD ENDED**  \n**Mar 31 ,** | **Jun 30 ,** | **Sep****30,** | **Sep 30 ,**  \n**2024** | **2024** | **2024** | **2024**  \n(In thousands, except per share amounts)  \n**Net** **loss** | $ | (6,358 | ) | $ | (4,143 | ) | $ | (2,334 | ) | $ | (12,835 | )  \nDepreciation and amortization expense | 396 | 403 | 381 | 1,180  \nIncome tax expense (benefit) | -- | -- | -- | --  \nInterest expense (income) | 7 | 180 | 588 | 775  \n**EBITDA** **-** **non** **GAAP** | $ | (5,955 | ) | $ | (3,560 | ) | $ | (1,365 | ) | $ | (10,880 | )  \nNon cash stock-based compensation expense | 924 | 838 | 458 | 2,220  \n(Gain)/Loss on foreign currency translation | 1,426 | 544 | (2,650 | ) | (680 | )  \n**Adjusted** **EBITDA** **-** **non** **GAAP** | $ | (3,605 | ) | $ | (2,179 | ) | $ | (3,557 | ) | $ | (9,341 | )  \n**Net** **loss** | $ | (6,358 | ) | $ | (4,143 | ) | $ | (2,334 | ) | $ | (12,835 | )  \nNon cash stock-based compensation expense | 924 | 838 | 458 | 2,220  \n(Gain)/Loss on foreign currency translation | 1,426 | 544 | (2,650 | ) | (680 | )  \n**Adjusted** **net** **income** **(loss)** **-** **non** **GAAP** | $ | (4,008 | ) | $ | (2,761 | ) | $ | (4,526 | ) | $ | (11,296 | )  \n**Weighted** **average** **common** **shares** **outstanding** **basic** **and diluted** | 54,262,790 | 54,306,041 | 54,453,006 | 54,340,583  \n**Loss** **per** **common** **share** **—** **basic** **and** **diluted** | $ | (0.12 | ) | $ | (0.08 | ) | $ | (0.04 | ) | $ | (0.24 | )  \nNon cash stock-based compensation expense | $ | 0.02 | $ | 0.02 | $ | 0.01 | $ | 0.04  \n(Gain)/Loss on foreign currency translation | $ | 0.03 | $ | 0.01 | $ | (0.05 | ) | $ | (0.01 | )  \n**Adjusted** **net income** **(loss) per** **common share** **- basic** **and**  \n**diluted** **-** **non** **GAAP** | $ | (0.07 | ) | $ | (0.05 | ) | $ | (0.08 | ) | $ | (0.21 | )  \n  \n![](https://www.globenewswire.com/newsroom/ti?nf=OTI2OTgyMiM2NTcxOTU2IzIwMjg2MTU=)![](https://ml.globenewswire.com/media/Yzc4YWYyZjUtZGJkYS00ZDllLTkxZWQtNjdlODE4Y2UzNjlhLTEwNDAwMTk=/tiny/CytoSorbents.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/7d55186f-ce46-45ab-b1c2-fd0c843890aa/small/logo-1200x628-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/7d55186f-ce46-45ab-b1c2-fd0c843890aa)\n\nSource: CytoSorbents\n\n  * [Print Page![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/print-regular.svg)]()\n  * [Email Alerts![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/envelope-regular.svg)](/email-alerts)\n  * [RSS Feeds![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/rss-solid.svg)](/rss-feeds)\n  * [Contact IR![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/users-medical-regular.svg)](/contact-ir)\n\n\n\nRequest Email Alerts\n\n[](#)\n"
        },
        {
          "title": "CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification",
          "url": "https://ir.cytosorbents.com/news-releases/news-release-details/cytosorbents-submits-health-canada-medical-device-license",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![CytoSorbents Home Icon](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/logos/Home_Icon.svg) ![CytoSorbents logo](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/logos/CytoSorbents_Logo.svg) ](https://cytosorbents.com/)\n\n  * [Overview](/investor-relations)\n  * [Press Releases](/press-release)\n  * [Financial Results](/financial-results)\n  * [Events & Presentations](/events-presentations)\n  * [Stock Quote](/stock-quote)\n  * [Analyst Coverage](/analyst-coverage)\n  * [SEC Filings](/sec-filings)\n  * [Investor FAQ](/investor-faq)\n  * [Corporate Governance](/corporate-governance)\n\n\n\n# Press Release Details\n\n« [Back](#)\n\n## \n\nCytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification\n\nNov 04, 2024 \n\n| \n\n[PDF Version](/node/11981/pdf)\n\n  * **_Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack patients requiring surgery_**\n  * **_Successful MDSAP certification confirms compliance with Health Canada and U.S. FDA quality management system requirements, replacing FDA audit and inspection if required_**\n  * **_Health Canada and U.S. FDA regulatory decisions expected in 2025_**\n\n\n\nPRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- [CytoSorbents Corporation](https://www.globenewswire.com/Tracker?data=cEx2DnKOYPidhVmn2nzmhyH08hFIvHvlZ-IhtwOP7P4vlT1M9O7OBJYObXWMvp_aNbFWhQoMeBIPF2r-EgZvip1GPya0pQZ2TQ_7EEJQDtM=) (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the submission of its DrugSorb™-ATR [Medical Device License (MDL) application to Health Canada](https://www.globenewswire.com/Tracker?data=6Mb4Gjy4MqIUrhohZjbS1ziANpXtQRC5Qdn8K01mFxBCiNjIPmxjTpAVUQRwrOw-rbfMuLafwTNmmlo8EX78S-GxEt-BN9YWDrtSkLwlWlS5q5NMnXgw97Fv2J6wlaeiLCqq5sjRSEHOQpEZyWkoh3V8-qBkron3oJUDZu4Su1TIyxFpNykdclMOBtJoF9VTYwc_HnhYMwvnSvZTOv9T4ecfnf2DS-bmlbovQdeFGkoMla08OhawPHk7S-p2ZYwcXLOAjxElgsORrDBRO8PBkjYJoRX8ygN9rCoCilu_ojcAGRfB13PeK9DpyCd8MR3h) on November 1, 2024, concurrent with receipt of its [Medical Device Single Audit Program (MDSAP) certification](https://www.globenewswire.com/Tracker?data=6Mb4Gjy4MqIUrhohZjbS10h1p_wzERoHok4TtNHvoWqUffkyBYO-8RhsFtHg-JI_J59rY04V57OHOQoEGPhsO6wyPsO-mbOnqYa-zRY1aMXgstjTOpRgh8BzQVwNEyL3RhqCM8P0PT3Rq28DpdyCW-dmo0TzoPRAkxEQWoO7-TY=). DrugSorb-ATR, an investigational medical device, targets the ability to allow safe and timely coronary artery bypass graft (CABG) surgery in patients with acute coronary syndromes (ACS) on the blood thinning drug ticagrelor (Brilinta®, AstraZeneca). The Canadian MDL application follows the Company's DrugSorb-ATR U.S. Food and Drug Administration (FDA) De Novo filing which is now under substantive review.\n\n“We are excited to have now submitted DrugSorb-ATR for marketing approval in both the U.S. and Canada. We are also pleased to have received MDSAP certification from our Notified Body, a single audit program that certifies medical device manufacturer compliance of its quality management system with the standard and regulatory requirements of [Canada](https://www.globenewswire.com/Tracker?data=X0w5o9BD3Sf3vfcK6aD1_YDJuHIf3eVyYhYsjLdZAkb510f25yn4Gg5WnUPUSmqHibw69u6ZyvKRihhHdG3PCgFIoPb-NOrQ0aEPQKoBCaQa5qDMt82INDiLCJdBUJEfoanHjW1poM_wvAXml0N1CgO2bIM04j2GiNiFtxIL4y8BGgrOYX9QpW6LfQmFAotuVri8I4i2AXNBrKMaa-8mNJyj_xB2ZlIb5j8jfloYty4SvRWIzHTqjYhKKPhshFXb), [the United States](https://www.globenewswire.com/Tracker?data=aSaZkMhjQW1wFYuJkkq_YYp3zK17ynOaAiG4yy-UJY9FGFH1MuSpnDWNP83sknTFj7U5bispHsb85Vt1TYiwncTzQTnr0NwFSaKrRvd_UEE2j9lTK3X9Us5RpkqtcPbqK9tI7aIGTrLhICSqzAGrfNm0Zdu8yyfUCjWn78bSBVcABJsQxavw_6bbHgK7vLb6KzgkKlmRYkTYs44PMj0HFA==), Brazil, Japan, and Australia. Successful MDSAP certification is a key regulatory milestone and pre-requisite for filing our MDL application to Health Canada. In addition, [U.S. FDA accepts MDSAP certification](https://www.globenewswire.com/Tracker?data=Wa0l4bEQ2ypNoZfmaDfPF8B89RPdoh3zEitMKbfMr94YcnLgDRnOxkThR_XV0YFwFJucv9OgIF1MWqRbQ8BLrq_N--UIqId8U59cI6icF1pmrCQzA0urgaRlFg2msz5H04sKuVPKpcfv8ezJaC0CKiVl724PXrf-ni5fUjo--1ejT23iW5IqErzxh4XwhCbRDwwL6B53Rdt7FODRdfKEpxdtjPCvHQ_wGcOUKZx55EI=) and audit reports as a substitute for routine Agency inspections, if required,” stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents.\n\nDr. Chan continued, “National treatment guidelines in Canada preferentially recommend ticagrelor over other antiplatelet agents, resulting in its near universal adoption in acute coronary syndrome (ACS) treatment protocols. Because of this, a future Health Canada approval of DrugSorb-ATR has the potential to improve the standard of care in heart attack patients requiring CABG surgery by enabling safe and timely surgery while eliminating treatment delays that expose patients to additional risk and consume valuable hospital resources. We believe the high rates of enrollment from Canadian sites in the STAR-T trial have helped to validate the unmet medical need and strong interest in DrugSorb-ATR among cardiac surgeons for this application. Meanwhile, the market for DrugSorb-ATR, if approved, is concentrated in approximately 20 cardiac surgery centers in Canada where we believe our team can quickly launch and support our therapy in this important market. We expect regulatory decisions in 2025, with Health Canada likely preceding FDA.”\n\nTicagrelor is a blood thinning drug frequently administered in the hospital to patients suffering a heart attack. If patients are not eligible for a coronary stent, they will often require CABG surgery to restore blood flow to heart muscle. Current guidelines recommend the delay of surgery by three to five days to allow “washout” or natural elimination of the drug to reduce the high risk of serious and potentially fatal perioperative bleeding from the use of the blood thinner. The 140-patient North American pivotal STAR-T randomized, double-blind, sham-controlled trial evaluated the safety and efficacy of DrugSorb-ATR in patients undergoing urgent cardiac surgery on ticagrelor to reduce the severity of perioperative bleeding complications compared with patients operated without the device. The safety and efficacy data in CABG patients from STAR-T form the basis of our marketing approval submissions.\n\n**About the Canadian Regulatory Pathway**\n\nThe Health Canada Medical Device License (MDL) authorizes manufacturers to import or sell Class II, III, and IV medical devices in Canada. The license ensures that these devices meet the necessary safety, quality, and efficacy standards as per the Medical Devices Regulations. MDL requires MDSAP certification.\n\nMDSAP is a program that allows the conduct of a single regulatory audit of a medical device manufacturer’s quality management system that satisfies the requirements of multiple regulatory jurisdictions, including Canada and the U.S.\n\nA final regulatory decision on a DrugSorb-ATR MDL is expected from Health Canada in 2025. DrugSorb-ATR is not yet granted or approved in the U.S. or Canada.\n\n**About CytoSorbents Corporation (NASDAQ: CTSO)**\n\n[CytoSorbents Corporation](https://www.globenewswire.com/Tracker?data=cEx2DnKOYPidhVmn2nzmhyH08hFIvHvlZ-IhtwOP7P4rNBDHH3nrFBKGh-MAVNIZGnbnvIi5CGpkXJ6krmC3oHNJpk848vT9AulJTpzyOGL8iWgRMbz4oqjFwqncR4WU7zagpLI1ATIWP01qvI1LIvWqrbKvBExm5SKyo8ZuVAAnBHBWq7MkoeVxEKu7Kr2gK8exPqua3Y-NT-10F-msm-w--g7jSBtpzu3nmFYKKyNY2dp0C5dW2-KPmDeohDlWz0F6WIejOjhApfFMfTOB1M_NYcABm1wMZyHoQ1lHhpa_0V_d4a6JTsVAScQL9-2N6EvsbnYNL3uEEYRA58eiS8Ln8kaOT_1XyFjS2_ghe4cIG8INwQ-ozF-xPZ71aG4djvo6px4JzJoHpZJmwFSCa_jksP9bZUy4vVzuguFQGPIpBbvd_7btEuJI5xcOyxIjGN_9lHon3K-brb-R3895RcRG1QUBa1_HLFc5hKfIJC0h_CvtZG8qgvw8UXo9IjjP) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, ECMO, heart-lung machines). CytoSorbents’ technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding and 2) the removal of inflammatory agents in common critical illnesses such as sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.\n\nCytoSorbents’ lead product, [CytoSorb](https://www.globenewswire.com/Tracker?data=cEx2DnKOYPidhVmn2nzmh-dlJnMNcuH6BDQ9bXzAPwORvEPOilwwP50shQv23JRyE5dz5vODd_o49jrFQBMeGPqg-mOYduY7_S5z0euHcBh1lObN6XI9ltl5Wtjk2053yoh92rrlsb0Pfv_yFC3J-qPBnxieKA17SSUVnV6WEG-zlHR4zaBSU_t4uK4blZzFNjdnXaTGdTDOn7M80os9SHljfDNh-iuCySm5S8cFKnGMwpOvlwNpnLOO2rRxd5m5iPo4enbl6JRDkvws1E-bm2nHIxgGsi8lv9RJ0mHxpoFuW0eWX20S8Bcm9EF-hUZXV3UUZ5NKd8i3TElhqWBq10xeBg3KfZwYyOaJbQ04jL37NWY-Dv29r-x3vDG7sV6aWGcE21PcIi8poj-lz_5EJUUkvp6J5GFK8pjiphzsEPNn3yKkinbSkyGLkvrKHrccCS3LLOs48dgGI2EFPpBq_30ZWxQhDtFB0gnDtDPkanrmudpbhsAhBNqoZ6YG4KKg3L0ns-K2JzMZEEyR9ajn2FEeG7KI7SKGq9fv922VkBYKPbVPYFrOxEBHBjWfmK8ic2BW-dm2ZO8-t5ZcetUwl9X-oq5JrIZpo48cwhc_KnxtpqKcCwDJI4SrcdXuuFrUTVjie4QSlji38nLlS1juxfjPj35apbUFHuimY106YLI=)[®](https://www.globenewswire.com/Tracker?data=yRHAmtIAPNXBTV6p9htrobHSHI4-1XAVHv4zTgoRUSoHZKoP0mQtvQRLwwmNOgCDY9msX5iFliuZoTxK0NX4sgpDPAUBJ-VKyqUmrrq2dyvF8CYyfz0pO3VcE8bd2EaXOgwaCFR5GAtjH1D8IlCZKVhAuZH1r3Ni44GvabWKfGkNeKjZr1qm4fNwvPEvWoJpvoKT7dsjg87ihGCCorspdkNhfrZqaIw0PBDZD7gI4UiQ8ZMqyQ4ZuY5I9umkBWQ3flPeEFkprfhcTGNdgQr2UM9tqp8faeGYF8Y19m0V_j2gtpMbslP9AQYLoaGMB_vz8jKG-aXZcILhjq4R68fkjOzDvD7dwpiMnd871wjrvQhLssnmJHa8EJ87jK-eg2omHiZDCPuP8xy1E6_34Z91E3VVbrD7US42ZcgKjrYysj8RA7a_fySETq5WTdg1x5OUU_wPT6e_bq8t7g9_elOhlMf2rD3dC2LDJ293AoQfgilD-Z2fmabB8HileOkPobUC7-01hN2cqpfd4LnjbaYxSL8UGAhD2mLoADvPdwW8CA44uqUYU4U5z7Uc1RriADjLcSJMcEYr3gD1adS_t27H70VMQ3KsZekGdGLugMt_TxvtgLmTbEkWqAyM9KtD6u_fSdCnDqnjuq9qDgU_CYDnb32QTOxU35R2dyqwHeO3OX0=), is approved in the European Union and distributed in 76 countries worldwide, with more than 250,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for [ticagrelor](https://www.globenewswire.com/Tracker?data=80BhiBb4pWCb0EDPWz_hlphNCag18xmVPUFGnL6F9e79irE2WGeNHlwaCIU671i6NLRob6nvERJF74Vk9frSS1KpAVSYCP3_oh872w0Yhi937GZuRfLbzucwV4sX9ZTCEpBG3KEqsyHzJQDWO-wLpZRixae5fKipza8yU3uqBpEboDZaN2D9PsacnU3evn_l7y_2jQvJKJVD6zclBdA2XigCm2HOxKbO-K8nzMV3sN3vsuO5FIVmWk7rLsSRyjwIZdSOuvW2ehqo_GGUU6Rt_MZE0zAKgzejrHRMyrZIlL4e3PvMfQeeJg-eTfVf14km0LzBoDwkMqGyXOC3EwxH7eDD0iQJRM8QTW-ZdQIVuA9Tjr_6UHtLpuLsRrZj777DVRSPohytUPOahSmEkpfxbuCga5i1_X758_Zk8gi-_qc_Wy87wDm-mcdtu9WzFiiyyS7UGmpX2YtjhW3pckxYQsJiWG5T0Mn9FllNKlB0P01i86hXQZtu6A4v3C0MAfHHRYAAYdAO49aKPP2ThV_c7Ku_vk3st8eL6ap5Urm9gZ-1tC2W8Kkq5L7TVNv6DnwtbGSH4DM2aTbXnrLdCJ5eDos-3VYl5OPCyzWXlSoplmh5-DnfajWW0TBeZ2DlzDfMmwQdBhCfltPyyn3a5PfmSHm_sGUs4vA9WLxlqWAxhr1Y5cipudGBMzQZ00vvcI7epBMRMOca-CQd1-2oOsHsYrShnoz4uyWQt--KlMhCxNLXfUm_MrBdEHnNFZT1mR4D6v827CdlR9Bkzk0g7zvTGZaD-4mkaZkYsaEPPV8N3FrSJ8hVV3CAI0lF4aTKtz75KsndOyGrXP14mlYR6UwUushB_uSm3PAwMrxwT3nY4U5xfzVre9SdDf3a4n5O2FUOapViHbFhhJpVC-oA8FqmMKRweYoR9ksE6WUp1odqhYCB3Ad1wSj2sWVuEgwRcj2ygNvVla59yrKFxhTfGGLhf6dt1Sbe4ZHqV4zBV2B_cTz24baoJvqahBiaiV7-eW-CjeLTXewmNujkRg64ZhBW99DfpP7b7IPqSCA-f9eja2bu1KHfxEEl1aNLFKAic5c0592cyElfYT9vEs9LC3vcnuzPo5lGOWLa2k85trCRzX2BpteXbOXBU5Q1qzYAZVhEjq7PJz02UBvYOJ2kNfqWLw==) and [rivaroxaban](https://www.globenewswire.com/Tracker?data=rG1Snt15N1tdEMPHRw9Qs-YS2Kv7KMzbs7w3o3Etnzcm-RSwe9H-eue-pKvcQSNyrkkk_CgsXpaqb6E6pn2HHUFRIMMLYxeLIBG9Z6rStuY8ykAp0JKAowpTW0TZ5FLDiR0nH-aijWR8hO0AhkudjYv_QtX84llnaLgBXUAQUlDv-T5vcjo7U5ytRyjBy6-ZhdntwoxXijaQCQSpwbgO-7HdKUt9hOWuHNhnbo-m9FWO5rej_AokAbaiYrooX729luF8m6v0JJULk-9c9Qt0jKzX48krudN0UwTP5h8SumZElggaYz1RH0ERpTgGP6DymCwzmZiTt_8DR8whnIWLXu8GIn5sEdkPtldaxGJP5KifK3_kbukTVFZxviraVtXunr8ILfrddtlRPRaAskM9ZMmj3UHU54IlF3FhXaIGp_ycMA0oecGENvstC0WSs84XX4kQWtQVyQnJMPhIrzyei3WKrJl7iNinFSzdC5P7sDq6kw4ugJam44N9kSHAW082qTNs1v-fCOg_QeN-iPvsdztDeW19yzUq6Z0h5JozGuHBnPYhCF9Sho4-8VzjnpnYhgTrUMWdT12T-N2Th3HIYkAoCdo_b7bHskpkt_Qzmv5tlMK1ZyHfoLgFUKU1y2GG6dnXfNLX1UabrMpyzQSTo23gG7uOepe_2Y33gkaqYAnhzyXCrLFhGQRxmebqdpJNpJY9yXDy4vBxhDV4m04fOVvVNs77sr8eqW4QhWa0f41pOiKUXOfAfQ9cWt63SASxISQ6Kai7KK51i3deZj1_JoJbOLaQF1qcg6KeCiv6GQ7Di7alsdAMaHxdnIpo7KeJuoTKZG-fA-UHwEnXPYB8OmNmO9jq48s3iSvjvOiNT3y6CyaAUCLnqEFZ0iV3-s69HB7RAuwehtg4nZ6vGTOwQKYVOK10MSzlMiSK-X00dCEQr2Dn-1EE3nqlExOpF3WS7y7xXVd0t9lcKEN5HelrfyKK0ZtL5zD0qeYEXTyHbQjfFuqFtwgiYTiIsp66quqhEfyMXzpSXJOPC9IAUNF4_XD_akLrZ4aPWv8ojpZEIzj3gxUleYtRmMFqskH4qJ32v9R99ePSWMJMhnJu_QBUMTF9lBfa2SQ2UVMDu4Lgx9zhZxxC6O0o-RPXz9PcC13xwcLQBc7FSFaHbDrVKPn-fhSCk-Tfdlj5LnzhBqN1ImLM15K_sOaUaV7SbN3NIFAo) removal in cardiothoracic surgery procedures. CytoSorb has also received [FDA Emergency Use Authorization](https://www.globenewswire.com/Tracker?data=HWjiSSOGQ3ZtmOuc1AFfMkaaVYnmI8WBtYautqcYgdc3McWPToUE4fEmJIwmTQbA-Gqwmbc3qf-3I3OeBOGqaiKigVby42-AZsLTILpUbUJOD2-jPcKo0B6_O6bCpYsUTHf3h42Tp_m3OCQhMbIP3ev17IrKJ4ONWcKF_OqMeSRGPG4y1NEf1L2J3vZ6l1KG_8z5jnjGbBRJ3HDUNsg_mWG73iFa1evMIzWAFgUVujcZmjU_TeKROcsG4IJGVwVp-tUNggL9Hwj8r_98LFCwgdtTNogUSFPhYdAH16JW7xnNN3BsDcC47wMavwgRQNCpcZ7uFODpIBx0YO7Nsxv5g95T0RQ54zAKzGfJfwWg09eKh-zu-lVWPRsjVX9j2SrjfFXjLwD4dyRwlCdOogP3Cpfexm0UJgByJUZz0XHXb2Nv52HimckCu1QES93wi_qYb3kBP0euV-srXsIx2p9yCbRYBwiRQG9u6ta0IpkqwMtM8V0wu5Jj6Oi5-LnjhmfqZkDXhrCK7DNu9hZF-scVjxB_JElkh0XoIuYDKEe1y46XSCkguYdNMo7hoKD2CZItKqtUiHcZhOLDBVwBllAC1fRJW-67SEP4ijeXtDxzokXvQ-B3EtQFVvLaTcx8mxtnP8lhZLJ6Ab4QZ3ootYtl1mV5AWnrxEVwC2AY7ghnSDhzZkUMR-XLl2FKJBsFHfpqz4cYQF29VvFGaOC4Z6w3WciEmmSPi72uCuT5eitHsY5VulHisZALbt2_ks-HxdQGw-hsr6fzasMX7CYHD9hPJopJg9IAHbMcqvFFQ29FxcfHsIYUmo70iw5BcplPsEnvfpQW3CG8UcHmZ51SJgofizYwhYX2ieu0fgw1Y6Cxt7FdEISWshtHzWOqJK4cRwPgjQI9c3_J0m6Js7uSy-aPK9XmjcQMlGJQ7RJEYJQoZpemhxbEoMnDCLkX99vhys1R8Gr50kIQhczqrlHWCb-rjuDRAx7fRj9KJWNAcOLIZXDS5NUBp7IEbSWDy0EhFbk-wN-wVU_Wps9ND86UsQ2esAzQQW9TcJhEb7VYwOVutJ3ZaNEnjcrh3mugVO0lMwTREeC0E1kSBN9yaIctgAvfruQ0T-dzmnJd2jPYpiCM4WKdYVvhkt6amph0aUv2mtmPPF6pYbpp-4FFbzxgh2RLnLpvAaRC5bERcJM7CKhlsvciXyqG8d26Y813XGu8HR1uXPYhQzeW6KRdkNZzl6rw9B18V0Ju_keFnqDMyLM0Cuw=) in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure, to reduce pro-inflammatory cytokine levels. CytoSorb is not yet approved in the United States.\n\nIn the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two [FDA Breakthrough Device Designations](https://www.globenewswire.com/Tracker?data=nAbPpJAM2_mLOoAem1gxZtlIPvMB-xItozhndzVNIKFx_DpUpDk6sKr9ul_Piue0WLTwcOpFbtVQa2LFPiHXkPSaPPF-6cwpZ91ZnUlfPZ9MMPh6cwF1EuFRRbzClDJjxLguZuIRinSgPP5DcQv0bq6x95NHtHoIEo7sjk_CUia3eLn4zTQN_rf6MD3Ia2-NwoStqRjg3qYco9eFqNdmX2Z8Yu3N6GQbNPwgyUmbD0B4WeLsErv1TQQMNL4FDVP6mknwhz_uKKkK67OYcvRYHdZjBDcPwPIwmlWnfduEpoIYwG37WDV85LmbxZ2Q2G6LFXdhQNJT7wPheMnX9MnWE1t3ZRBv7YhoPYOYtHEJkVFohlV2CpFZtbr1erQe-KptwwWRMdaJCu9wP1uDC2VHbFcKzjDWcqdF--9TaX-6enGtyMXiMkaX-UKzzBktsNUVwU7Uf6aMeCcJnqvglXv45ErDSCRPWa-yH9StuxSrofmfjjH9zzd0f_85qBTVfvqfGI0y37i0V4a0neD9yX0EKZdcxYGifuasNfAHi-xXGt_iiHqogbLtYCa9bDNeIAlFCFhoPBLdmmtluxTR4A-5OCLkbySQ9dLQ458kap8ZJJefepMriKAKkPuUZsVAn-cORp5qLCmGdZFWkg3v7fZUCcGJX5TsDt03HlmxgNOPMa7JkRfefhxH27dqgKiBRdvR42CUmvNX_j26mbtXww2t9n3pJlZuLeo19Ccsl7P1DB6GEX9OJRMcBs1lCjFxam6OD9IZqP2iPRiktim0zihcLvKG4k0tKbG0NagFghcddvHsH6uzbTL8A2q1Th4DxpyCfFtng0j_Vwh305gEDI3D0EzONF5WtXZ_BPu_hd-vdbsrF7019b732IpVCskxUsGPw6H-kEuSSbPrQDu-I4aI2X2aja_0EZ6x8h6wk8zLBGMFQOQx0EFfjiUZYARLm22uTbG9Q1-hHj6NCsy4Q-PGXvrrCP3qDGJaT0-UU_K3K54LOM41Lrta1UfBsXH-xW9yxQczDFkBpxVR38vBE-598WdQtAseUQmF_-5IzRhTYjenG3qYcuOL7HnStm5fhlkUSRbGyOMzJfXMCjss711PwEH7AFlHgX46PylzLuooGFP6hPLk6S7i8UBOrhxVLiCZs0q1_nYbvjpA6OkTqt36VYXKZcEVqb9BQEhke2bIiOCBe4ObFoO7Pu2Qn61f_urcIZVJc2YNoKCIi5Kxr0Hgh-nrIMM70e4mQxd_Fc-28Vu-5zZF94AX8fOJ3h4hC9qpGeo5nD0HLHuIPDOxvkthgaTzrMLaYbM6p7kL9w1zC_QsZWSTxFsIAYGDuN8--rcJAhUbKNnHjdgxUKoBRvsbBWNXfITDaM6trgVGOPzu8p60ouSiI2o83IJUwiKr_9L6sk4E9PTaIgr4oFJD0VKqKXzKirBvtUW-bdZLDrKYyZglX2kPfy-US5NhHk6zzLhABRbyoscXkUM4gbbRaYcUzBPly0cdyCO4_5Vk7SxKXtw=): one for the removal of [ticagrelor](https://www.globenewswire.com/Tracker?data=80BhiBb4pWCb0EDPWz_hltLh-bSPIsLSwVmv3YlbUzy_HJV77y4mU4Cgg9j7-XnBjk1zQlueJ1UObpDae8GYpBuUOOg7vUO-Ohd41286BJcbHiUfsl_1DdWPp9eshMS6X53UFKxuJ5N8u28-pmPnJmTl5LWuFNTc-xXJldpi9GOyVaAfFl5W-7JY2LlSD53sdO3spgBGD2GJp7HQC2CQ32qppTqN6L_Lz2A3EaBSdZ91hZGJhnmsEJ-hmYMNRWHvOfRQgIt8ASefA43LxCrNRv_5G7Qytxp-eK5wpSV_WKN-oZpyYugMzD1_Ai2wobaAbnBjJ64On6jPRw9OA-PVdzMt-_vxX_4yyIEYCxlWtHdtsurTr2oCcQ7kKDq4nSZoHuKpB9GuIrO3eTI9Z6xtqiG6km-cg789QXPR25NAFRvNQE0qamj3x3tpNFd5CdOCYWfRs5NBlUiZiqPZaG6z-JUDaQrMkPXPexIeLXXPuJT7OMY5wQ3G36vDH4ubDolJfqKW15sDwbWo3Qkdw_VkfX6nLOtMDrw1MG9GY23bf3hCfvr5KasaLAq7DTfLdFozVNhKtE7gHefC0AsnT-sUHnS2fQJeIMj7Ak0hYuzt-a5tLI4i_WY-rROCGvZD5rScSs6v-Kmz9J43LjHFQGaaaO6H70xGlArXZm1uzQFh5UiZPsPufQmQvcK_CGytEs8ETs91PygTu6wTdKXM1LO2XIa6H4mD3TA1Hsalc-5Ftkfaq820aW5G9Gus9Ds-MdfAA4IS5g9T1XRgaV00y8KpYh8J4yl3fGDCSS6zlkpzdDKc_n42sBQC9NPWbX-tj6PwY-hq69clOmvDJO_tLn99F86OxIT1haAujR3mje4sBCKEGRCOLPmzIGf2qnd4WYDXzN7Y1C2ygHVvJSRO4Zf8i2-48e8pGfevXON2GZuT-jvTH2g1DL4wLV1nghxdL14BYnvqoj4OQIlPyvQSYll6HQAtplk58vdkfhLtIg05bl1_c6mImhCC2XCfIoU9gZyikQ5geef_y8C4E_PN4t7GOQYJ-BLlu5MJIX-N1Gr7lN8RrkceXg_bENH6FnDQPViLIp-07aIr7fwZ-KUTsfhFUmyPxpeRRDYaNA9beOvJ8fvhAyDEhaF5JlGjQ06WoY89GvHq3GVOcV1K4Alye3B854Q4m8jOeA3HA84CooKUW_pKYOxGUo8ODgokrH6_B_oM_rt9HqQ8be5RBYZz0xuRl9XaqxeP_TGTCxk-rLgITSv0ITyF_N_HOsjLTMdTIKYeVLyVzvT48Jbl9WNlazMrcKLL77FAgbHQ_BFoFo81b-zG7KZsHVaq4o3EKBBqsOyI) and another for the removal of the [direct oral anticoagulants (DOAC) apixaban and rivaroxaban](https://www.globenewswire.com/Tracker?data=MS071rN3xZr9XwIz0kxdb8UcTGd8ovFpvwLvPXHIH67IEsEz0XUL_HkllodYqLtaMrIggAQyWwAVy4SHPR5eza9bHGwquBAkb3ZGI7MBS2gvxA0JZwiMGOD4VFLotuC0b2fL9NSMB-1-IjdNIN7axDOjL4hz8QoF0tsFzK4Bo6Zl1BSepUQVg8OYmJPUo3BqfVb9hNVT8pEsiokXwug9KC1bK9byizwRuzjSqiyp_OGVdlTF1neplkqJk8XxBo_nSF4829mvJV2gJvC1TqDQ5Gq6lP-JCsMsImeSMaNQi7rQHOFEGZDcgROGGdm9eOH9fjUHk-nNbZQtlEo-FDk4j3xNLA152wb9BKBR0tFDsXIILcQ7fAzM4KSG0APtYNMKLwepGGsLtSSx8IYTSBVm3b3YJTKA9clFTVOgFk6i9Q2KVfVSvRa9aZSbxfyUeTKxHjOw0HnxrEEOwQXON9y10svRGrnqi1B5IPzu9P1JjtT5EvXK0N7363gcF-i9VHb5KGUEKTneqT5-a6KhFjWDnVxYHNBlFRm54tAPLSDqwi4-4mmQ3pV6FaQFvH98mZhNhqd2RtYMs-eEX71J9Atbl4iWMvW6NTnCMbfAvVxAjsawyoriYeFZu6W3HD0nJpgDx7BVNrLAJRuVEgIC9xhnsSHRV-l2xtC7ys-3hMDRORX63VgHmivFIeLwMpDhKluCwBagYQcUu_zBfEGCBkAeN0I0Yskn2jRgBnTZ2mldjK8mcuWrc1j8TpSDSfFotTpxTprdkFYp3Orfh8-051g1HvyHwRV2FuD1SXcrTLATwJrhTPf5ycxkG7uWqRNAXimuo0DXgefrBr68I78NIrJVXQ6qoE4rFf1a9DSJPs9NEWdEZTwguORwC8quvc-PGmXESzQ02lhp7Nv28zmcmI3odZNkN_Er5eq8nq9CM5ntzbstMfWLqZ7phRgvuYxORUeGmvSr_NcvhUOxS4aejKec_GR2iPSGqcj2XhVjv2yCl3X_HslydP_oLiyjqTimF4Bh3K16vWKbguSHKtBna_ssYD2ymSCNHkc4_H64-6jSfsB7wRfH8vLlVvpwPt8ZR5KufB-z1b6aJSZiSR_bL3mc6x0nqjxcwXcjE6nyYSHkK74lFiTQ01doFvn_8gOKOqEXdiZdiknraM1k6ryr7vxFQTS-KOC9tbl-bZr-IOMse7xMZh3pEjm1yQc_QXYweSu3b2JtMJ2AGZXL6Pg73ldjaq8wPigDK7tlQ1fs-v_CCGPULqutDvo242VW94csy_spGZ2xrvKLT_-5JTLG5LdDuOvHkj_aVnNtga0Tpor7gZfWbz2uba6ZvwQskQp6VR_se_GsqqQHtsCrrwp6kh4bDZQuSzPVon2iVJX_373aOMr7c-pZrrNpdgrGnS_5vvn6RpqXk9eg5spo8ZpLzyYxLSSVIg7N4JuyQfYynuwh5Z6lF6e7jfYMYmsfg6gJk45KjcR7_JSlGa4PTq6teZEhF0h8EjgHBspumUpnEMYCezl1z6-OZB54eFTTx77Sp7G_yoXYvugR4TS7HQovot789Ue2tEmn82K9sYueO80QH90D8Y2OfM5omCF86sEK-ApMmwhc6-alqEv4DtHo9x5dz8SXJXEeaNSMQgwqb3HBKRwJy2oXucTBSbGporucONJitHf8CJKcpDnxH66TTx1mJk-SyA7czYJCB9WkwKttZ4J6ggVbmMeDBe1VLAOk5j5l2eHDcA2n_CEVJU6ZdVB5nInWYrBF82oEWOh_ozKPnRxvVZ4F4-lN3qIeH1dYP9_p4fc8oVPh13CYvncOQ7WRs7gGOIt580OM3DRBAqg7LIhCZLjAw36Y7me5l1L5PKC-) in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. In September 2024, the Company submitted a De Novo medical device application to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the antithrombotic drug ticagrelor, which was accepted for substantive review in October 2024. In November 2024, the Company received its Medical Device Single Audit Program (MDSAP) certification and submitted its Medical Device License (MDL) application to Health Canada. DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively.\n\nThe Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company’s website at [www.cytosorbents.com](https://www.globenewswire.com/Tracker?data=ja9Q5o8gJnxj_82ih_UyO2PwFCju--MsFDQ9FnAQvnLmj53w5h91dEv1haa0TtM8umkrKKBVeWsCPmGDj6JOJP3zHHumC8bgMrNna-fxjOWptjwdEsLEwh5UtxWB-7Bne3oB-0ZEf21B-0MzRRc9OEAVGpLR-4wqLo_1m0rw4HEQmi9aoOHN76x570YAVIqG1khMTlWNHbywW-oO_Oj6EUtbxXvrIUwDjzOqoP0YFuq9EvJOnMQJIcRNe5ixVkCncS2Mr7gelRBwX7S1eyNM7Meb_KTUGWLfw444b5cTUOjnIXA-icBlSAjdGvD2gQd0p0-lBqaCjULoi3dYecp58KH3yR0YwALiNWUqCgeupMuVww8uZO-0QF2jJVFI3mocQJZ6Uj5NfKWWADLVHRvMQM0jBHAYs5baYzMTv-qE7y6Zti067d7SO-EtZfWbFqqF-LES56XU19LGE1gEWrOrWQzqXJarh5rf2Nlfhkgs8oZfUx8qplZ9rsf7Q8caq4us) or follow us on [Facebook](https://www.globenewswire.com/Tracker?data=jD17q_9LmHc0Fk2M1Qltpon62Q2gMDS0Q-MhGGbMlWtRwGY4gtt4mHF_8SxreLqG14MMytp2kSWaIuVwiFCz1u_LPGX3iWMZ7qwc270rgRUqElqUFChiTiTN6MHAGN2RDx1c9mbjzHZfOkp9cnL54ZXB7H7nrt65t_IL5bd3WTSxm4fWqW-3LfDnLR76jPfYggAg_y1yL_5QokxgxgoW-4n2Ni96UejsXRnsAIEOfOzcN6sCCJnDP-sarD5yYBmj7yovDIkmtLF4dqRpPhjZoOeAWSVNpt4vSPfGHZv2zTOW9u9ZDLsR-grBTMPcSMvbVgWL_w-PdYZVU1GGyZm6nhhLOb7JNQPJ-prgBA58vDGKYZpZ4fcIIeznIO0n-yFolsxGxQGC3yJhGrzG-7fi9yv4iztof2H7hTQy19FiJrkBiaj9yk8PD6m-EHysIJhX) and [X](https://www.globenewswire.com/Tracker?data=WF63aZRk7-D7assLKJPD7hgJEz4HtYGv7UpzCwgjaGKE7Sz1wfBq7mqnROoUN0G-mLrK-BZdIcMw8Y_k2uFhSaBw06_PzqHpByc-hha7FBWZd27_D6ijeO5Qv2iragEJr8Y9ufEeOTfKX7bA-gUZfSafxmAhlJ0lr2w6POU_eV9NFkMlKFpbjH77gRYYMDzC__li19yi8D11cAikPAiI28WoPeBz4OOSO_Yv7gquaY93PKfIGDoXzSwPF4DgHr4JVGbps44NVNeNXJFwnN12F3G6_Jkme85stO3Y09kMhNI2cNFxS9tMjMUoagN3dPFhhvOGOzDolGfM4iniBHbYP2Dr9Ivp1UKmq9M9OrkOpqUPSkr-gZX-OPc8g2PuYSih). \n\n**Forward-Looking Statements**\n\nThis press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.\n\n**U.S. Company Contact:**Peter J. Mariani, Chief Financial Officer305 College Road EastPrinceton, NJ 08540[pmariani@cytosorbents.com](https://www.globenewswire.com/Tracker?data=3P3suDW-fRHzncQ0rd1frYhWzc9kVoXJaoBgLZCC2UMkyfVowZre1G85tEGP59TEpuV3WLlrj6WckQ0vs2jpjVyM5JhlHw2gzayFIcYsDOm7pW7R4HJ2mfhZcUO5tFOY)\n\n**Investor Relations Contact:** Aman Patel, CFA ICR-Westwicke [ir@cytosorbents.com](https://www.globenewswire.com/Tracker?data=uk6WLMlY4YIUCnvIP_llYU6K3U21TtT_KgopcI3AUvZ0jqWHX_K8r2wtfxwgJsrRNKF3VslTP7JQs2fzfygTObpYYRiC2IHsLVRYB1U7blDFFefuxuER9QtWhz0S3f90x1jvLD1Wpe-zeMxtQGXMf7WtOT3GKqnC6wPlkf8iZdAbRcWw6DYrvFUeNvQf12m1r5WxcSIE7wYhlNthJxy_uLcjRsPzOMDkevq_d5-bvyE9YhLrC7ObapM2zI-H2KJDoIrQBLNha8Uj5sOjmecPhQvQDqTtbHwnZBzrXff0GFS4BE3dusVps4m8mtZbAAuqxGmr2xxlIdnV8ZN-a9cl64UJ1ta0UwY5yPX7jy0oqmRpprysPAbQl0dOPWi6uQe6RdhcauEr3Be_qP22lYg5yVw0V8BN_kEnENo2YvOmJwKZUlDv6g1PnhapHrsnjxzLdas7oBkp-cSLGWkWeYfGp385bBSNo37GN9Gbatv3Ap4IZimIfOf1QKQ2Haymw-QdaHjM-Mn647EkJTaTxLTOWfJHCy06Pb0gI-hE2Y9cvjlkCvc-9T9ZBY2Ygbh2WLeO-lYeRgmxrxyuF5QWmHf4ZFWPlDqPmUZSUBIRneAyeSiCk5QRsLe5jkN2F94r7vvzjI4M02x2GEoGN5KWQaEAyrJMadUZ-IM0IY-i6UEw7cgDYDp44tff3TLh5BJ6aXN8F1j5y0iRYgnL058scCLTm8eMVo8H0by59MRLF0L6epOT7g5yKkpR3m3QMQNNjzQxqhiyGzxWsahaFsE-VpxFhg==)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI2NjgwMSM2NTYzNDUxIzIwMjg2MTU=)![](https://ml.globenewswire.com/media/MzBlNGQ0MTQtNjg2Ny00ZjBjLWIwMTItMGUwOGZiMTk4Yjg0LTEwNDAwMTk=/tiny/CytoSorbents.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/7d55186f-ce46-45ab-b1c2-fd0c843890aa/small/logo-1200x628-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/7d55186f-ce46-45ab-b1c2-fd0c843890aa)\n\nSource: CytoSorbents\n\n  * [Print Page![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/print-regular.svg)]()\n  * [Email Alerts![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/envelope-regular.svg)](/email-alerts)\n  * [RSS Feeds![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/rss-solid.svg)](/rss-feeds)\n  * [Contact IR![](/sites/g/files/knoqqb93131/themes/site/nir_pid7601/dist/images/icons/users-medical-regular.svg)](/contact-ir)\n\n\n\nRequest Email Alerts\n\n[](#)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Investor Presentation",
          "url": "https://ir.cytosorbents.com/static-files/ddbd620c-1c87-43d1-aaa6-c385ecbe85d3",
          "content": "\n"
        },
        {
          "title": "Investor Presentation",
          "url": "https://ir.cytosorbents.com/static-files/bcf7175a-a572-4a1e-99f8-e7a2feaac1d6",
          "content": "\n"
        }
      ]
    }
  ]
}